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The term epigenetics refers to heritable changes in gene expression that do not 
involve changes in the DNA sequence. A large number of enzymes, which act 
mainly on histone tails and DNA, carries out epigenetic modifications, 
influencing several biological mechanisms. 
The interplay between epigenetic enzymes and chromatin is highly complex, 
and despite great progress has been made in understanding the role of these 
proteins in biological contexts, much remains still unknown. On the other hand, 
it is widely reported that specific epigenetic modifications are associated with 
disease states, therefore epigenetic enzymes represent potential therapeutic 
targets. However, the lack of specific and robust screening methods to evaluate 
epigenetic enzyme activity limits the identification and development of 
epigenetic modulators. 
In this scenery, this thesis is focused on the development of a robust and widely 
usable combined screening platform to identify small-molecule modulators of 
epigenetic proteins. Different biochemical and biophysical techniques were 
used in order to evaluate potency, selectivity, binding and mechanism of action 
of the modulators synthesized in the Epigenetic Medicinal Chemistry 
Laboratory (EMCL). 
As model systems, among all the epigenetic enzymes, the attention was focused 
on the acetyltransferase p300, the methyltransferase SETD8 and the readers 
Tudor domains of PHF20. By the use of a combined approach, a set of small-
molecule modulators was identified. These compounds could be used as 
chemical probes to further investigate the biological role of these enzymes and 
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1. INTRODUCTION 
1.1 Epigenetics 
The concept of Epigenetics was pioneered by Conrad H. Waddington in 1942 
as “the branch of biology which studies the causal interactions between genes 
and their products, which bring the phenotype into being.” Epi comes from the 
Greek word over, and thereby epigenetics is the study of the molecular, cellular, 
and environmental aspects of heredity, which are not explained by simple 
changes in the underlying DNA sequence. In fact, epigenetic processes 
influence the chromatin structure but not the gene sequence. Unlike somatic 
mutations and other genetic alterations which irreversibly alter the genes, 
epigenetic processes are reversible and thus provide environmental plasticity 
and cell adaptation to new microenvironments. Moreover, the chromatin 
structure has an intrinsic memory and it is transmitted over cell generations.1  
Chromatin is made up of building blocks called nucleosomes. Each nucleosomal 
unit contains an octamer of four histone proteins (H2A, H2B, H3 and H4) 
around which genomic DNA is wound almost twice. The nucleosomes undergo 
recurrent structural rearrangements through DNA unwrapping, rewrapping, and 
histone core disassembly and assembly, and they are subject to covalent 
modifications. These modifications, called epigenetic marks, have been 
identified on both DNA and histones. Whereas DNA can primarily be 
methylated, histones are capable of carrying a wide array of Post-Translational 
modifications (PTMs). A large number of PTMs have been discovered on the 
histone tails that protrude from the nucleosomal core and are freely accessible 
to epigenetic enzymes.2 
Histone modifying proteins have been categorized as “writers”, “erasers” or 
“readers” (Figure 1.1). Writers are those epigenetic enzymes that lay down 
epigenetic marks on amino acid residues on histone tails while erasers catalyse 
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the removal of these marks. Readers are those proteins that contain domains that 
recognize these histone marks and bind to them. 
 
Figure 1.1: Schematic representation of the main mechanisms for epigenetic 
modifications. 
 
1.2 Epigenetic Writers 
Epigenetic writers are chromatin-associated proteins that catalyse the deposition 
of the PTMs mainly on histone tails and introduce dynamic modifications that 
respond rapidly to environmental changes.3 
Among all the possible chemical modifications that can be introduced 
(methylation, acetylation, phosphorylation, ubiquitination, sumoylation, 
propionylation, butyrylation, crotonylation, ADP-ribosylation, citrullination), 
histone acetylation and methylation are the most abundant and widely studied. 
These modifications are carried out by Acetyltransferases and 
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Methyltransferases respectively, which are able to modify both histone and non-
histone substrates. 
1.2.1 Lysine Acetyltransferases (KATs) 
Lysine Acetyltransferases (KATs) mediate the transfer of an acetyl group from 
acetyl coenzyme A (acetyl-CoA) to the ε-amino groups of lysine residues in 
histones and other proteins. After the acetylation, the positive charge of lysine 
is neutralized and, in the case of histones, the interaction with the negatively 
charged DNA backbone is diminished, producing an open chromatin status that 
is responsible for the promotion of gene expression.3 
KATs have been classified into type A, which are nuclear proteins that acetylate 
chromatin-associated proteins and histones, and type B, which are located both 
in the nucleus and in the cytoplasm and acetylate newly synthesized cytoplasmic 
histones to promote their nuclear localization and deposition onto nascent DNA 
chains. While KAT1 is the only KAT in the type B group,3 type A KATs can be 
classified into different families by structural homology and biochemical 
mechanism of action. Despite several KAT families have been identified, only 
four have been extensively studied: the Gcn5-related N-acetyltransferase 
(GNAT) family (KAT2),4 the E1A-associated 300 kDa protein (p300)/CREB-
binding protein (CBP) family (KAT3), the MYST family (KAT6)5 and the 
regulation of Ty1 transposition gene product 109 (Rtt109) family (KAT11). 
Among all the above-mentioned acetyltransferases, one of the most interesting 
protein is p300, which is a key enzyme in higher eukaryotes where it acts as an 
effector in several signalling pathways. Because of its fundamental role in 
different biological functions, this protein is the first target on which this thesis 
has been focused. 
1.2.1.1 p300/CBP 
p300 and CBP are two acetyltransferase enzymes expressed in humans and most 
higher eukaryotes. p300 (also called EP300 or KAT3B) is so-named because it 
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is about 300 kDa in size (with 2414 amino acids). p300 was firstly reported in 
1985 and 1989 in studies looking for proteins that bind E1A, an adenoviral 
oncogenic transcription factor. Meanwhile, CBP (also called CREBBP or 
KAT3A) is composed of 2441 amino acids and was reported for the first time 
in 1993 in a study of proteins that bind CREB, a transcription factor that binds 
cAMP response elements (CREs). Because of the high sequence homology 
between CBP and p300, together with the little sequence homology between 
them and other acetyltransferases in the human genome,6  the two proteins are 
now collectively referred to as p300/CBP and classified as a separate family 
class of KATs. 
Despite they were first identified for their binding to E1A (p300) and CREB 
(CBP), it has been later demonstrated that these two proteins contribute to 
transcriptional regulation through their histone acetyltransferase activity.  
p300 and CBP contain several protein interaction domains (Figure 1.2); in 
particular, the structure of their HAT domain suggests a “hit and-run” (Theorell-
Chance) catalytic mechanism in which, after binding of acetyl-CoA, the lysyl 
residue of the substrate peptide snakes through the p300 tunnel and reacts with 
the acetyl group. Interacting with a large number of transcription factors, CBP 
and p300 are involved in different cellular processes and misregulation of their 
activity is frequently implicated in many human diseases.  
 
Figure 1.2: Domain architecture of p300. NRID, nuclear receptor interaction domain; 
TAZ1, transcriptional adaptor zinc-finger domain 1; KIX, kinase-inducible domain of 
CREB-interacting domain; Bd, bromodomain; RING, really interesting new gene; 
PHD, plant homeodomain; HAT, histone acetyltransferase domain; ZZ, ZZ-type zinc-
finger domain; TAZ2, transcriptional-adaptor zinc-finger domain 2; IBiD, IRF3-
binding domain. 
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Modifications to histone lysines associated to p300/CBP have been studied as a 
major factor in cancer pathogenesis, but they also play a role in 
neurodevelopmental disorders, neurodegenerative, autoimmune and 
cardiovascular disease, metabolic and psychological disorders. 7, 8 
For instance, mutations in the CBP (rarely p300) gene causes Rubinstein-Taybi 
syndrome, characterized by a short stature, moderate to severe intellectual 
disability, distinctive facial features, and broad thumbs and first toes. Moreover, 
CBP and p300 were demonstrated to be involved in hematopoietic homeostasis, 
such that mutations in the CBP/p300 interaction domain of different 
transcription factors were found in hematologic malignancies and chromosomal 
translocations involving CBP or p300 genes are associated with leukemia and 
lymphomas. CBP and p300 promote prostate cancer progression by activating 
androgen receptor-regulated transcription and colon cancer progression by 
microsatellite instability and they are involved in the development of drug 
resistance. 8  
The inhibitors of CBP/ p300 described so far are of two types: the compounds 
that inhibit the binding of other proteins targeting the interacting domains and 
the derivatives that directly affect the acetyltransferase activity. To the first class 
belong the bromodomain-interacting molecules, such as the 5-
isoxazolylbenzimidazoles recently reported as potent and selective ligands, 
those targeting the TAZ1 domain, such as chetomin, and those (namely sekikaic 
acid and lobaric acid) targeting the KIX domain. The second class inhibits the 
enzymatic activity of the HAT domain; in addition to many non-selective 
inhibitors (e.g., the natural products anacardic acid,9 garcinol,10 curcumin,11 
plumbagin,12 and their analogues or semisynthetic derivatives), the only 
selective p300 HAT inhibitors described to date are the bisubstrate inhibitor 
Lys−CoA conjugate,13 which is not cell permeable, the pyrazolone C646,14 
described as competitive versus acetyl-CoA and noncompetitive versus a 
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histone substrate, and the isogarcinol derivative LTK14,15, 16 again not very cell 
permeable and hardly optimizable due to its structural complexity. 
For all the above considerations, there is still need for selective modulators of 
CBP/p300 activity not only as useful tools to dissect the role of their 
physiological and pathological role but also as potential leads for the 
development of drug candidates for specific diseases.17-19 
1.2.2 Protein Methyltransferases (PMTs) 
The protein methyltransferases (PMTs) catalyse methyl transfer from their 
universal methyl donor, S-adenosyl-L-methionine (SAM), to a nitrogen atom of 
lysine or arginine side chains forming S-adenosyl-L-homocysteine (SAH) as a 
byproduct of their mechanism. 
In contrast to acetylation, histone methylation does not affect chromatin 
structure directly because this chemical modification does not change the 
charged state of an amino acidic residue. Depending on each specific residue, 
methylation is associated with activated euchromatic genes or with silenced 
heterochromatic genes. Moreover, each type of methyl mark represents a 
specific modification that is recognized as a docking site for chromatin-
associated proteins that maintain chromatin architecture or regulate gene 
expression.3  
The PMT enzyme class is composed of two distinct families of enzymes, based 
on their active site structure and on the amino acid to which they transfer methyl 
groups: the protein arginine methyltransferases (PRMTs) and the protein lysine 
methyltransferases (PKMTs). There is one exception to this general structural 
bifurcation of the PMT class: the enzyme DOT1L acts as a lysine 
methyltransferase, but its active site structure is most closely aligned with that 
of the protein arginine methyltransferases.20 
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1.2.2.1 Arginine Methyltransferases (PRMTs) 
Arginine methylation is a common post-translational modification that has been 
implicated in signal transduction, gene transcription, DNA repair and mRNA 
splicing, among others.  
Three types of methyl arginine species exist: ω-NG-monomethyl-arginine 
(MMA), ω-NG,NG-asymmetric dimethyl-arginine (ADMA) and 
ω-NG,N’G-symmetric dimethyl-arginine (SDMA).  
Protein arginine methyltransferases are classified into type I or type II, 
according to modification types: although all PRMTs catalyse the formation of 
a monomethyl-arginine intermediate, type I PRMTs (PRMT1, 2, 3, 4, 5, and 8) 
can catalyse the production of asymmetric dimethyl-arginine, and type II 
PRMTs (PRMT5 and 7) are able to catalyse the production of symmetric 
dimethyl-arginine.21 
1.2.2.2 Lysine Methyltransferases (PKMTs) 
Histone lysine methylation is a marker of both transcriptionally active and 
inactive chromatin, depending on the residue that is methylated, its degree of 
methylation (mono-, di-, or trimethylation), and its position within the gene and 
in the genome. Except for DOT1L and WRAD complex,22 all known PKMTs 
contain a conserved SET (Su(var)3-9, Enhancer of Zeste, Trithorax) domain 
harbouring the enzymatic activity.23 To date, more than 50 PKMTs have been 
identified and characterized. On the basis of sequence homology, SET-
containing KMTs can be divided into different subfamilies: the SUV39 family, 
the EZH family, the SET2 family, the PRDM family and the SMYD family.24 
Several studies demonstrated that many SET domain PKMTs catalyse site-
specific methylation of lysine residues in non-histone proteins, including 
transcription factors and other chromatin modifying enzymes, illustrating that 
lysine methylation is a widespread post-translational modification in signal 
transduction.25 
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Among the several PKMTs identified so far, SETD8 is the second enzyme on 
which this thesis is focused. In the following paragraph there will be a brief 
description of its mechanism of action and its implication in biological 
processes. 
1.2.2.2.1 SETD8 
SETD8 (also known as PR-Set7, SET8, or KMT5A) is the sole mammalian 
enzyme known to catalyze the monomethylation of histone H4 Lys20 
(H4K20me1). SETD8 protein expression is tightly regulated during the cell 
cycle, being highest during G2/M and early G1 and nearly absent during S phase. 
SETD8 activity is essential in cell cycle progression and in the DNA damage 
response and it has been associated with mitotic chromosomes during cell 
division. SETD8 promotes transcriptional repression and mediate 
transcriptional activation. Recently, a direct involvement of H4K20me1 
modification in the assembling of the pre-replication complex (pre-RC) on the 
replication origins of metazoans was demonstrated, highlighting the important 
role of SETD8 in this process. Besides H4K20, SETD8 methylates p53 at lysine 
residue 382, preventing p53 promoter binding and thereby inhibiting apoptosis. 
In regard to its function and role in human diseases, SETD8 is overexpressed in 
different types of cancer tissues and cancer cell lines including bladder cancer, 
non-small cell and small cell lung carcinoma, chronic myelogenous leukemia, 
hepatocellular carcinoma and pancreatic cancer. Furthermore, SETD8 is 
implicated in cancer invasiveness and metastasis through its interaction with 
TWIST, a master regulator in epithelial-mesenchymal transition (EMT). 26-28 
Selective SETD8 inhibitors would serve as useful chemical probes to further 
investigate the cellular effects of SETD8 inhibition in both normal and diseased 
cells and as lead structures for the development of anticancer therapeutics. 
However, only few inhibitors have been reported so far for this enzyme.29-33  
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Very recently, three quinone-containing inhibitors endowed with cellular 
activity were identified from a high-throughput screening campaign, yet they 
irreversibly inhibit the enzyme, probably by a covalent bond with a Cys 
residue.29 These consideration prompted the research to the development of new 
small-molecule scaffolds for SETD8 inhibition. 
 
1.3 Epigenetic Erasers 
The erasers are enzymes responsible for the specific removal of epigenetic 
marks deposited by writers. Epigenetic erasers are classified in several groups 
of enzymes and the most studied ones are histone demethylases (HDMs) and 
histone deacetilases (HDACs).  
1.3.1 Histone Demethylase (HDMs) 
Until a decade ago, histone methylation, together with DNA methylation, was 
considered a stable chemical modification. This view changed with the 
discovery of lysine-specific demethylase 1 (LSD1) and the identification of the 
JMJC domain-containing lysine demethylase family. Several members of the 
histone demethylase family appear to be genetically amplified and 
overexpressed in some human tumours and these findings make the histone 
demethylases very interesting targets for drug discovery. 
1.3.2 Histone Deacetylase (HDACs) 
HDACs are enzymes responsible for the removal of the acetyl group of lysine 
residues in histones. After histone deacetylation, the positive charge of lysine is 
restored, promoting the condensation of chromatin and consequently 
transcriptional repression. HDACs are divided into five classes based on their 
phylogenetic comparison with yeast enzymes. Class I comprises HDAC1, 
HDAC2, HDAC3 and HDAC8; class IIa consists of HDAC4, HDAC5, HDAC7 
and HDAC9; class IIb includes HDAC6 and HDAC10; class III comprises the 
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sirtuins from SIRT1 to SIRT7; and class IV contains only HDAC11. Enzymes 
from classes I, II and IV require a zinc ion for catalysis, whereas sirtuins are 
NAD+ dependent enzymes with protein deacetylase and ADP ribosylase 
activity.3 
More than 10 years ago, it was discovered that deregulation of HDAC activity 
in association with chromosomal translocation was involved in the stimulation 
of leukemogenesis. To date, several studies have provided evidence of aberrant 
acetylation and altered expression of HDACs in cancer cells and tumour tissues. 
Therefore, using HDAC inhibition to reverse epigenetic aberrancies in cancer 
cells is a powerful approach for the treatment of several tumour types and four 
HDAC inhibitors are now approved: vorinostat34 is used for cutaneous T-cell 
lymphoma and is being explored for treatment of other cancers, romidepsin35 is 
used for peripheral and cutaneous T-cell lymphoma, belinostat36 is used for the 
same lymphomas but can be used in combination with other drugs to treat 
ovarian cancer and panobinostat37 is used for the treatment of multiple 
myeloma. 
 
1.4 Epigenetic Readers 
Epigenetic readers are specialized domains able to recognize and bind to 
specific epigenetic marks produced by the writers and erasers. Chromatin 
readers are able to identify not only different modified amino acids, but also 
different modification states of the same amino acid.  
The most known reader domains of histone PTMs can be divided in different 
families able to recognize acetyl (Bromodomains) and methyl marks (Tudor, 
Chromo, MBT, PWWD and plant agenet domains, which belong to the “Royal 
Superfamily”). 
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1.4.1 Bromodomains 
Bromodomains bind to acetylated lysine and they are probably the best-
characterized epigenetic readers. The structure of these readers is highly 
conserved. More than 50 bromodomain proteins are encoded by the human 
genome and they can be clustered in nine subfamilies according to sequence 
homology.3 
A well-known example of a bromodomain family is the BET (Bromodomain 
and extraterminal domain family) that includes four protein members (BRD2, 
BRD3, BRD4 and BRDT), which contain a tandem bromodomain at the N-
terminal.38 These proteins play a decisive role in the regulation of transcription 
and cell growth; in addition, BET proteins are usually part of large nuclear 
complexes that are involved not only in transcription processes, but also in 
chromatin remodelling, replication and DNA damage. Hence, dysregulation of 
BET proteins has been reported in several diseases.39 
 
1.4.2 The Royal Superfamily 
The royal superfamily includes Tudor, Chromo, MBT, PWWD and plant 
Agenet domains; all the members of this superfamily possess a structurally 
related barrel-like protein fold, which is composed of 3 to 5 antiparallel β-sheets 
and forms the core structure. This conserved structure probably originated from 
a common ancestor that specifically recognized protein methylation. In distinct 
royal subfamilies, additional structural elements flanking the core structure 
contribute to the binding properties of its members. Members from each 
subfamily recognize either methylated lysine or methylated arginine residues in 
target proteins using a common binding mode, in which an aromatic binding 
pocket in the barrel accepts the methylated side chain. The pocket is usually 
composed of 2 to 4 aromatic residues, which provide electrostatic and 
hydrophobic contacts to accommodate the inserting methylated ligand.40  
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1.4.2.1 Tudor Domains 
Among all the methyl readers of the Royal Superfamily, particularly interesting 
are the Tudor domains. Mammalian Tudor proteins can contain a single Tudor 
domain alone, multiple tandem Tudor domain repeats or one or more Tudor 
domains in conjunction with other types of domain. The Tudor protein family 
can be largely divided into two groups, one containing methyl-arginine binding 
Tudor domains and the other containing methyl-lysine binding Tudor domains. 
Most methyl arginine binding Tudor proteins are predominantly involved in 
RNA-related processes while methyl-lysine binding Tudor proteins are often 
implicated in chromatin biology, a general feature of the other royal 
superfamily members.41  
Specifically, this thesis is focused on the recently identified Tudor domains of 
PHF20, which have a crucial role in the stabilization and activation of the 
tumour suppressor protein p53.42 
1.4.2.1.1 Tudor Domains of PHF20 
The PHD finger protein 20 (PHF20/GLEA2/HCA58) was initially described as 
an immunogenic antigen that elicits a strong antibody response in glioblastoma 
and adenocarcinoma patients. Later, it was shown that PHF20 can 
transcriptionally activate p53 and be downregulated through phosphorylation by 
the Akt kinase. PHF20 was also identified as a component of the “male absent 
on the first” (MOF) lysine acetyltransferase, which together with O-linked β-N-
acetylglucosamine transferase, isoform 1 (OGT1) form the nonspecific lethal 
(NSL) complex.42 
This protein is a component of some mixed-lineage leukemia (MLL) 
methyltransferase complexes with the core components MLL, ASH2L, WDR5 
and RBBP5. PHF20 is a multidomain protein and it comprises two N-terminal 
Tudor domains, a central C2H2-link zinc-finger domain and a C-terminal zinc-
binding PHD domain (Figure 1.4). 
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Figure 1.4: Domain architecture of PHF20. 
 
Although little is known about its cellular role, the domain organization of 
PHF20 and its association with MLL core complexes suggest it to function as a 
transcription factor. Previous studies have indicated that the second Tudor 
domain is capable of binding methylated residues (preferentially dimethylated 
ones, one of the most common is H4K20me2) on histone tails, while no such 
function has been ascribed to the first Tudor domain.43 Moreover, the second 
Tudor domain of PHF20 interacts specifically with p53 peptides 
monomethylated or dimethylated at Lys370 or Lys382.  
Whether by mutation or overexpression, Tudor domains of PHF20 were found 
to be implicated in cancer and other diseases through aberrant binding of 
chromatin, which results in aberrant activation or repression of genes.  
 
1.5 Epigenetics and Drug Discovery 
Over the last decade, the cellular machinery that creates the epigenetic 
modifications has been the subject of intense scientific investigation. As 
previously discussed, epigenetics play a fundamental role in all the biological 
processes and modulating epigenetic mechanisms is highly relevant for many 
diseases. Because of the importance of epigenetic proteins in physiological and 
pathological processes, great efforts have been done in the discovery and 
development of small molecule modulators of chromatin modifying proteins. 
Despite all these efforts, to date only six epi-drugs are available in therapy (four 
inhibitors of HDACs and two of DNA methyltransferase) and few other 
modulators of some specific epigenetic proteins (EZH2, BRD4, LSD1, DOT1L) 
are currently in clinic phases. On the other hand, there is a large number of 
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enzymes for which no modulators have been reported. Therefore, despite recent 
advances in epigenetic modulators development, the challenge of identifying 
potent and selective molecules remains still open. 
One of the main reasons that led to the lack of modulators is that not all the 
epigenetic enzymes are druggable, because of unfavourable pocket features as 
well as the competition with cofactors for targeting the active site.44 
Proteins belonging to the families of HDACs, HDMs, HMTs and 
bromodomains are druggable, indeed robust and selective chemical probes are 
available to study these enzymes. On the other hand, for example, it has been 
very difficult to find potent, selective, and drug-like small molecule inhibitors 
of HATs. Beside the druggability, the identification and development of 
epigenetic modulators is also affected by the lack of specific and robust 
screening methods to evaluate their activity. 
From a practical standpoint, developing assays to screen compound libraries for 
the identification of small-molecule modulators of epigenetic enzymes is not 
straightforward. In most cases, the primary screening is based on biochemical 
assays, which allow to evaluate the effect of the compounds on the activity of 
the enzyme. An ideal biochemical assay should reproduce the activity of the 
protein in the cellular context. However, many epigenetic targets exist as large 
complexes of proteins and, in some cases, these complexes are necessary for 
their activity, so the use of isolate proteins may be misleading. In addition, the 
substrates used are not always canonical histones (often peptides are preferred) 
and this choice could affect the results.  
Cellular assays for epigenetic proteins have also proven to be somewhat 
complex. For many epigenetic targets, the effects of inhibitors in cell culture 
often take several days to see histone mark changes or effects on target genes, 
while phenotypic responses may require up to 7 to 10 days to be observed. In 
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addition, there is a lack of antibodies to detect effects on target proteins and 
even fewer for specific sites.45 
In the following paragraphs, there will be an overview of the most widely used 
biophysical and biochemical methods in the drug discovery process for 
identification of epigenetic modulators. 
 
1.6 Biophysical Methods  
Biophysical methods are well-established in many areas of drug discovery. 
Application of these methods was once restricted to a relatively small number 
of scientists using specialized, low throughput technologies and methods. Now, 
automated high-throughput instruments are available in a growing number of 
laboratories. 
Many biophysical methods are capable of measuring the equilibrium binding 
constants between pairs of interaction partners including protein-protein, 
protein-small molecule, and protein-nucleic acid interactions, and they can be 
used to measure the kinetic and/or thermodynamic components controlling 
biological processes in which they are involved. For a full characterization of a 
binding process, the determination of stoichiometry, the binding mode and any 
conformational change associated with such interactions are issues that should 
be addressed. The biophysical methods that are now available represent a 
powerful toolbox of techniques that can effectively deliver this full 
characterization. Biophysical methods are increasingly considered as a primary 
approach for hit finding. Among all, thermal-shift assay (mainly Differential 
Scanning Fluorimetry), calorimetry assays, optical biosensors and 
thermophoresis are techniques that have been recently successfully employed at 
this stage.46 
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 1.6.1 Surface Plasmon Resonance (SPR) 
Surface plasmon resonance (SPR) is a label-free detection method that has 
emerged during the last two decades as a suitable and reliable platform for 
biomolecular interactions. The technique allows the measurement of 
interactions in real-time with high sensitivity and without the need of labels, 
immobilizing target biomolecules on the sensor surface while a solution of 
ligand is flowed over the surface. Since it was first introduced in the early 1990s, 
SPR has been proven to be one of the most powerful technologies to determine 
specificity, affinity and kinetic parameters of a protein-ligand interaction. 
Surface plasmon resonance occurs when a photon of incident light hits a metal 
surface (typically a gold surface). At the incidence angle of total internal 
reflection, a portion of the light energy couples with the electrons of the metal 
surface layer, which then oscillate with the light wave. The electrons moving 
are called plasmons, and they propagate parallel to the metal surface. The 
plasmon oscillation in turn generates an electric field whose range is around 300 
nm from the boundary between the metal surface and sample solution. The 
defined SPR angle, at which resonance occurs, is dependent on the refractive 
index of the material near the metal surface. Consequently, when there is an 
interaction between the target biomolecules immobilized onto the surface and 
the analyte solution, a small change in the reflective index occurs and it is 
detected (Figure 1.6.1).47  
 
- 17 - 
 
Figure 1.6.1: Typical set-up for a Surface Plasmon Resonance biosensor48. 
 
The main advantages of this technique are: 
 Real time analysis. 
 Kinetic information derived. 
 Label free technique: no need for radioactive, fluorescent or any other 
labelling. 
On the other side, operator have to face with several problems:49 
 Mass transport can affect kinetic analysis. 
 Any artefactual refraction index change (other than from the interaction) 
can also give signal. 
 One of the interacting molecules must be immobilized on the surface. 
 Lack of sensitivity when monitoring low molecular weight ligands. 
1.6.2 Differential Scanning Fluorimetry (DSF) 
Differential Scanning Fluorimetry (or Thermofluor assay) belongs to a class of 
technologies that investigate the interactions between a biological target and its 
binding ligand. This assay use the well-established thermodynamic principle 
that the thermal stability of a protein, often quantified as the midpoint of thermal 
denaturation or melting point (Tm, the temperature at which both native and 
unfolded states are equimolar), can be altered by a binding ligand in a 
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concentration and potency-dependent manner. In a Thermofluor assay, a 
compound with a low fluorescence signal in a polar environment (such as in 
aqueous solution) but with high fluorescence in a non-polar environment is 
added to a protein solution. The fluorescence of the solution is monitored while 
the solution is heated. When the protein chain begins to unfold, the hydrophobic 
core becomes exposed and the signal increases until the protein is completely 
denatured. Thus, the temperature of hydrophobic exposure at which half of the 
protein population is unfolded, is determined (Figure 1.6.2).50, 51 
 
 
Figure 1.6.2: Typical recording of fluorescence intensity versus temperature for the 
unfolding of protein with and without the ligand in presence of SYPRO orange. 
 
The commonly used fluorescent reporter dyes in thermal shift assays include 
Sypro Orange, Nano Orange and Sypro Red. Sypro Orange is usually the 
preferred choice because of its large intensity change upon binding to unfolded 
proteins. Intrinsic fluorescence from buried aromatic residues can also report 
protein unfolding as in the case of the nanoDSF. The basis of label-free 
fluorimetric analysis of protein unfolding lies in the properties of the fluorescent 
amino acid tryptophan. Since tryptophan is a hydrophobic amino acid, it is 
mostly located in the hydrophobic core of proteins where it is shielded from the 
surrounding aqueous solvent. Upon unfolding, tryptophan is exposed, and its 
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photophysical properties are altered. By detecting changes in tryptophan 
fluorescence intensity and its emission peak shift, the transition of a protein 




Figure 1.6.3: nanoDSF principle. 
 
DSF is a useful screening method for the following reasons: 
 Use of small amount of protein. 
 Label-free and no-immobilization required. 
 Easy optimization of assay conditions. 
 Fast assay preparation and data analysis. 
Likewise any other type of assay, this method has also intrinsic limitations: 
 Not all biomolecules are responsive to fluorescence based thermal shift 
assays. In general, proteins with large hydrophobic surfaces, such as 
membrane-embedded, lipophilic, complex-forming or misfolded 
proteins, produce high background of fluorescence as a result of dye 
binding before melting. 
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 The assay is adversely affected by false positive or negative results: a 
weak binder that associates promiscuously to multiple sites on the 
protein surface may appear as a more potent hit.  
 Interference by many detergents in the assay buffer. 
 Possible competition of the reporter dye with the ligand. 
1.6.3 Microscale Thermophoresis (MST) 
MicroScale Thermophoresis (MST) is a powerful technique to quantify 
biomolecular interactions. It is based on thermophoresis, the directed movement 
of molecules in a temperature gradient, which strongly depends on a variety of 
molecular properties such as size, charge, hydration shell or conformation. 
Thus, this technique is highly sensitive to virtually any change in molecular 
properties, allowing for a precise quantification of molecular events 
independent of the size or nature of the investigated sample. During a MST 
experiment, a microscopic temperature gradient is induced by an infrared laser: 
the directed movement of molecules through this microscopic gradient is 
detected and quantified using either covalently attached or intrinsic 
fluorophores (Figure 1.6.4).53, 54 
 
Figure 1.6.4: Typical signal of a MST experiment. Initially, the molecules are 
homogeneously distributed and a constant ‘‘initial fluorescence’’ is detected. Within 
the first second after activation of the IR laser, the ‘‘T-Jump’’ is observed, which 
corresponds to a rapid change in fluorophore properties due to the fast temperature 
change. Subsequently, thermophoretic movement of the fluorescently labelled 
molecules out of the heated sample volume can be detected.  
 
- 21 - 
MST not only allows for a precise determination of binding constants, but can 
also be used to derive additional information about the molecular mechanism of 
the investigated interaction.  
From different points of view, MST technology is superior to other methods in 
determining the parameters of molecular interactions. The advantages of MST 
technology are: 
 Low sample consumption. 
 Robust and sensitive detection (broad concentration and size range). 
 Rapid analysis. 
 No surface immobilization required. 
 Close to native protein conditions (possibility to work without 
labelling). 
 Live detection of aggregation, sticking and precipitation effects. 
On the other side, the technique suffers of the following drawbacks: 
 For a label-free analysis, at least one Tryptophan in the protein sequence 
is needed. 
 Absorption or Emission phenomena of small molecule compounds can 
interfere with protein signal. 
 Target and substrate must be soluble in the same buffer conditions. 
 
1.7 Biochemical Methods  
Biochemical methods are the most common techniques used for the study and 
characterization of small molecule compounds activity in drug discovery. While 
biophysical methods allow interaction studies between the compound and the 
target, biochemical assays give a quantitative measure of the ability of the 
compound to influence target activity. Biochemical assay development begins 
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with a purified enzyme preparation that demonstrates catalytic activity on a 
specific substrate in a cell-free context. Usually, procedures for enzyme assays 
are well documented or cited in literature, but even accurate observance gives 
no guarantee of an unequivocal outcome: the same assays performed 
independently may yield quite different results. In fact, the enzyme activity 
depends on multiple factors and the understanding of particular features of each 
enzymes is required. The enzyme activity depends decisively on defined 
conditions with respect to temperature, pH, nature and strength of ions and 
enzyme assays can only be reliably compared, if such conditions are strictly 
observed.55 
Many different approaches are available to measure enzymatic activity and can 
be differently classified. The most commonly used assays are based on the 
measurement of radioactivity and fluorescence.  
1.7.1 Radioactivity Based Assays 
Traditionally, assays based on radioactive probes (usually tritiated or iodinated 
ligands) have been successfully used to determine enzymatic activity because 
of the high sensitivity of the technique and the possibility to perform 
experiments on unmodified receptors expressed in native tissues and even in 
transfected cells. However, the use of radioactive ligands as tracers in these 
assays presents several drawbacks, both technical and financial. Technically, a 
classic radioactivity assay cannot be performed in a homogeneous format. 
Consequently the assay requires multiple washing steps before reading the 
radioactivity. This need adds complexity to the procedure and makes these 
assays more difficult to perform in high-throughput screening leading to extra 
cost. Additionally, the washing steps prevent any possibility of carrying out 
kinetics experiments on a single sample. Over the past decade, strategies such 
as scintillation proximity assays (SPA), which can be performed in 
homogeneous conditions, have been developed. SPA utilize microscopic beads 
containing scintillant: the interaction of these beads with β-particles, generated 
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by the radioactive decay of tritium or iodine, releases photons that may be 
measured with scintillation counters or charge-coupled device (CCD) imagers. 
A variety of SPA bead formats allows utilization of various substrates, but these 
assays are still expensive due to the production cost of beads. 
A second technical drawback rely on the nature of the radioactive probe: it is 
difficult, in part for health reasons, to perform saturation assays that necessitate 
high concentrations of radioactive ligand. Furthermore, due to the hazardous 
nature of the compounds, the use of radioactive probes has some restrictions in 
term of radioactive waste disposal, delimitation of working area and staff 
medical follow-up. As a result, other techniques have been introduced to replace 
the use of radioactive assays, such as fluorescence techniques, without 
completely supplanting them.56 
1.7.2 Fluorescence Based Assays 
Among the most popular enzyme assays, the fluorescence-based ones are 
largely used in screening campaigns. These assays are commonly based on 
synthetic substrates that incorporate a chromophore, whose fluorescence 
properties change as a result of the enzyme reaction. The key advantage of these 
substrates is that the assay is simple and the signal produced is directly related 
to the enzyme-catalysed reaction. If the fluorescent product is soluble, the assay 
is well-suited for microtiter plate based assays. To date, almost all examples of 
fluorescent substrates focus on a small family of fluorophores and 
chromophores, in particular umbelliferones, nitrophenols, fluoresceins, 
rhodamines and BODIPY dyes, all of which are relatively large aromatic groups 
which tend to influence both substrate binding, catalytic turnover, and 
solubility.57 
With the aim to overcome the limitations of traditional fluorescence-based 
assays, in the last few decade there was the introduction of other new 
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luminescence based techniques. Among all of them, one of the most widely used 
is the Alphascreen technology. 
1.7.2.1 AlphaScreen Technology 
An AlphaScreen assay utilizes proximity-based fluorescence detection through 
the tethering of donor and acceptor beads by a protein-ligand interaction (Figure 
1.7.1). 
 
Figure 1.4.1: Principle of the Alphascreen assay technology.  
 
Initially developed underneath the name LOCI® (Luminescent Oxygen 
Channeling Immunoassay), the reagents and bead technologies for drug 
discovery are currently exclusively commercially available under the name 
AlphaScreen by Perkin Elmer. In this assay, the photosensitizer phthalocyanine 
is dissolved on a polystyrene donor bead. Excitation with 680 nm light induces 
phthalocyanine to convert ambient oxygen to singlet oxygen molecules with a 
4 μs half-life. These molecules can diffuse 200 nm freely through solution. If a 
polystyrene acceptor bead is within the lifetime of the singlet oxygen species, 
the singlet oxygen will react with thioxene derivatives on the bead, resulting in 
a dioxetane product followed by a diester fluorescent product. If the emission is 
at 615 nM, the assay is called AlphaLISA: both assays rely on the same Donor 
beads but use different Acceptor beads. AlphaScreen Acceptor beads are 
embedded with three dyes: thioxene, anthracene, and rubrene. Rubrene, the final 
fluorophore, emits light detectable between 520-620 nm. In the AlphaLISA 
Acceptor beads, anthracene, and rubrene are substituted with an Europium 
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chelate. The Europium (Eu) chelate is directly excited by the 340 nm light 
resulting from the conversion of thioxene to a di-ketone derivative following its 
reaction with singlet oxygen. The excited Europium chelate generates an intense 
light detectable within a much narrower wavelength bandwidth centred around 
615 nm. In contrast to the AlphaScreen, the AlphaLISA emission is therefore 
less susceptible to interference by either artificial or natural compounds that 
absorb light between 500-600 nm. 
In both cases, the detection of the chemiluminescent readout depends on binding 
of the protein and its related ligand. Typically, the donor bead captures 
substrates (by the biotin-streptavidin interaction) while the acceptor bead 
interacts with the modifications on the substrate, after the enzymatic reaction. 
The interaction of protein and substrate results in chemical energy transfer of 
acceptor and donor beads, culminating in a luminescent signal. Lack of binding 
fails to bring acceptor and donor beads into sufficiently close proximity and the 
singlet oxygen decays without the production of light. Since the beads are 
coated with hydrogel, non-specific interactions are minimized, providing a large 
signal-to-background assay window.58, 59  
However, Alphascreen may be sensitive to different types of interferences. For 
example, antioxidants or other quenchers of reactive oxygen species like metal 
ions can strongly affect the emitted signal, as well as biotin-like compounds can 
compete for the interaction of biotinylated substrate with Donor beads. 
Moreover, since the Alphascreen detection is only based on a fluorescence 
intensity measurement, coloured compounds absorbing in the 500-600 nm 
wavelength range can artificially decrease the signal and therefore may be 
detected as false positives in HTS.60 
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2. AIM OF THE WORK 
Epigenetic enzymes are involved in the development of several diseases and, as 
previously discussed, they are considered very interesting targets for drug 
discovery. The complexity of these proteins, together with the lack of a 
complete understanding of their biological role, are responsible for the limited 
number of currently identified modulators. 
Different methodologies are available for the identification of epigenetic 
modulators (Chapters 1.6 and 1.7), nevertheless to date there is not a gold 
standard approach for the evaluation of their activity. It is worth mentioning that 
in a drug discovery programme it is necessary to use different technologies. The 
reasons of this need are different. First, each technique suffers of intrinsic 
limitations that could affect the outputs, as previously reported, so it is necessary 
to validate data. In addition, a single method is not suitable to deeply 
characterize the modulators activity (for example binding, mechanism of action, 
potency and so on). Furthermore, the use of different methodologies allow the 
identification of pan-assay interference compounds (PAINS), which encompass 
some 400 structural classes (for example enones, catechols, isothiazolones and 
so on). Usually, during the screening of compounds libraries, the activity of 5-
12% of compounds does not depend on a specific, drug-like interaction between 
molecule and protein. PAINS can give false readouts in a variety of ways. Some 
are fluorescent or strongly coloured. In certain assays, they give a positive signal 
even when no protein is present. Other compounds can trap the toxic or reactive 
metals used to synthesize molecules in a screening library or used as reagents 
in assays. These metals then give rise to signals that have nothing to do with a 
compound’s interaction with a protein. Other PAINS coat a protein or sequester 
metal ions that are essential to a protein’s function, or they may alter proteins 
chemically without fitting specifically into a binding site.  
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All of these mechanisms prevent further attempts to improve the biological 
activity of a molecule by modifying its structure. The only method to discover 
PAINS is to use orthogonal assays that can give different readouts, so it is 
possible to define “true hits”. 
In this scenery, the aim of my phD project was to develop a robust and widely 
usable combined screening platform to identify small-molecule modulators of 
epigenetic enzymes (Figure 2.1). To overcome the limitations of each technique 
and with the aim to identify “true hits”, different biophysical and biomolecular 
techniques were exploited to interrogate three epigenetic proteins (p300, SETD8 
and Tudor domains of PHF20) and we validated the outputs. It is important to 
highlight that the use of multiple technologies enabled also a deep 
characterization of modulators activity, allowing the determination of binding, 




Figure 2.1.: Combined approach to interrogate epigenetic enzymes. 
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3. RESULTS AND DISCUSSION 
3.1 p300 
3.1.1 SPV106 analogues as modulators of acetyltransferase activity 
Different approaches have been used to identify p300 modulators, but only a 
limited number of small molecule inhibitors have been described, with various 
degrees of selectivity and cell permeability. Ethnomedicine has inspired the 
identification of a few natural products, including anacardic acid,9 garcinol,10 
curcumin,11 plumbagin,12 and guttiferone A61 as inhibitors of different classes 
of KATs. Among them, in the Epigenetic Medicinal Chemistry Laboratory 
(EMCL) we focused our attention on anacardic acid. Anacardic acid, a small 
molecule compound extracted from cashew nut shell liquid which is known to 
have antitumor activity, inhibits acetyltransferase activity of p300, but it’s not a 
selective inhibitor.9 
In 2008, EMCL reported on the activity of a series of long-chain 
alkylidenemalonates (LoCAMs) as protein acetyltransferases modulators. The 
design of LoCAMs was inspired by the structural simplification of anacardic 
acid (Figure 3.1.1).62, 63  
 
Figure 3.1.1: From anacardic acid to LoCAMs. 
 
One of these compounds, the diethyl pentadecylidenemalonate 1 (SPV106), has 
a unique activity profile. This compound exhibits inhibitory properties against 
p300 with a potency comparable to that of anacardic acid, and it simultaneously 
enhances the acetylating activity of PCAF. Therefore, it is the first mixed 
activator/inhibitor of protein acetyltransferases.62, 63 
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As a result of its peculiar activity profile, derivative 1 was successfully used as 
a chemical probe in a study that correlated Duchenne cardiomyopathy with 
PCAF-mediated lysine acetylation levels of connexin 43.64 It was also examined 
during investigations of the role of KAT enzymes in the regulation of the 
extinction of conditioned fear and neuronal plasticity.65 More recently, 
treatment with compound 1 has been shown to reverse alterations in human 
cardiac mesenchymal cells obtained from diabetic patients and restore cellular 
function.66 
The uncommon biological properties of derivative 1 prompted us to explore the 
structure-activity relationships of LoCAMs. First, we focused on the alkyl chain 
and the flexibility of the scaffold:62 we found that variations in the alkyl chain 
length influenced the activity profile of KAT modulators, whereas all other 
modifications, such as variations in flexibility/rigidity of the core structure and 
the introduction of substituents, were detrimental.62 Indeed, not only the 
selectivity toward different KAT enzymes, but also the inhibitory and activating 
properties, varied depending on the substitution pattern.62  
As a further exploration of the structure-activity relationships of this class of 
KAT modulators, and with the aim of identifying potential structural features 
that differentially affect the activity of acetyltransferases, my project started 
with the synthesis of a number of 1,3-dicarbonyl derivatives (Figure 3.1.2). The 
synthesized compounds formally derived by the replacement of one or both 
ester functions with keto- or carboxylic acid groups while the alkyl chain length 
was kept constant.  In addition, because it was previously found that the diketo-
analogue of compound 1 (derivative 2d, Figure 3.1.2) retained inhibitory 
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Figure 3.1.2: 1,3-Dicarbonyl derivatives 2a-e, 3a-d, 4a,b, 5a,b, 6a,b, 7a,b, and 8a-f. 
3.1.1.1 Chemistry 
Novel SPV106 derivatives 2-5 were prepared by Knoevenagel condensation of 
a 1,3-dicarbonyl derivative with the appropriate alkyl aldehydes. The aldehyde 
used, if not commercially available, were prepared from the corresponding 
alcohol by oxidation with 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO),67 
(Scheme 3.1.1). Derivatives 2a-e, 3a-d, and 4a,b were prepared by reacting, 
respectively, pentane-2,4-dione, ethyl 3-oxobutanoate, tert-butyl 3-
oxobutanoate, or malonic acid with the appropriate aldehyde in 
dichloromethane using piperidine and acetic acid as the catalysts (Scheme 
3.1.1).  
 
- 32 - 
 
Scheme 3.1.1: Reagents and conditions: a) alkyl aldehyde, AcOH, piperidine, CH2Cl2, 
RT, 2–12 h; b) TFA/CH2Cl2 (5:95), RT, 30 min. 
 
The hydrolysis of tert-butyl esters 3c,d was performed with trifluoroacetic acid 
(TFA), yielding the corresponding 2-alkylidene-3-oxobutanoic acids 5a,b. By 
Knoevenagel condensation of ethyl 3- oxobutanoate and tert-butyl 3-
oxobutanoate with alkyl aldehydes, derivatives 3a,b and 3c,d were obtained, as 
mixtures of E and Z isomers. After the separation of the two isomers by silica 
gel chromatography, it was observed a spontaneous interconversion of the 
compounds. For this reason, compounds 3a-d and the corresponding acids 5a,b 
were tested as the E/Z mixtures. Alkylthiomethylidenepentane-2,4-diones 6a,b 
and alkylaminomethylidenepentane-2,4-diones 8a-f were obtained in high yield 
(Scheme 3.1.2) by reacting, respectively, the appropriate alkyl amine or alkyl 
thiol with 3-(ethoxymethylene)-2,4-pentanedione 9 in THF at reflux.68 
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Scheme 3.1.2: Reagents and conditions: a) alkyl amine, thiol, or alcohol (n=11, 12), 
THF, reflux, 2 h. 
 
Alkyloxymethylene-2,4-pentanediones 7a,b were obtained in good yield under 
the same conditions from the corresponding alkyl alcohols. Unfortunately, 
compounds 7a,b were unstable even in presence of low amount of water. 
Therefore, any attempt to purify these derivatives by chromatography was 
unsuccessful. Moreover, because an aqueous medium is required for biological 
screening, any further purification efforts was abandoned. 
This pool of SPV106 analogues synthesized was used to develop a screening 
strategy, using biophysical and biochemical techniques.  
3.1.1.2 Biophysical Screening: Surface Plasmon Resonance Assay 
To avoid time-consuming, expensive assays, all compounds were preliminarily 
screened using a Surface Plasmon Resonance (SPR)-based binding assay. As 
discussed in the introduction section, this biophysical technique is well suited 
for a primary screening.69 Recently, at EMCL, an SPR-based binding assay was 
established and successfully employed to study the real-time interactions 
between small-molecule derivatives and p30062, 63 as well as other epigenetic 
targets.70 
In this project, SPR was used for the identification of compounds able to bind 
to at least one of the acetyltransferase enzymes (p300 and/or PCAF). Thus, the 
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human recombinant p300 (aa 1284-1673) and PCAF (aa 492-658) catalytic 
domains were immobilized (up to  ̴10 000 response units (RU)) on the flow cells 
of the biosensor chip, and 1,3-dicarbonyl derivatives 2-8 were injected at 
various concentrations (from 25 to 100 µM) over the protein surface. To 
decrease false positives related to detergent-sensitive and aspecific aggregation-
based binding, 0.005% of Surfactant P20 was added to the running buffer in all 
experiments. In addition, to evaluate potential non-specific binding, all 
compounds were injected on an immobilized myoglobin. The binding of each 
compound was read in real time as the change in mass at the sensor surface. 
After injection, running buffer was allowed to flow over the surface, and the 
dissociation of compounds from the surface was observed.  
These experiments showed that tetradecylidene- and pentadecylidene-
substituted pentane-2,4-diones, malonic acids, and 3-oxobutanoic acids (2c,d, 
4a,b, and 5a,b, respectively) efficiently interact with the immobilized proteins, 
as demonstrated by the concentration-dependent responses and the clearly 
evident exponential curves during both the association and dissociation phases 
(the sensorgrams for compounds 2d, 4b, and 5b are displayed in Figure 3.1.2). 
For the compounds 2d, 4b and 5b equilibrium dissociation constant (KD) values 
were derived from the ratio between kinetic dissociation (kd) and association 
(ka) constants, obtained by fitting data from all injections at different 
concentrations of each compound, using the simple 1:1 Langmuir binding fit 
model of the BIAevaluation software. The compound 2d showed a KD of 5.85 
x 10-5 against p300 and of 2.74 x 10-5 against pCAF, while for the compound 
4b the KD obtained was of 4.32 x 10-7 against p300 and of 1.53 x 10-5 against 
pCAF. Regarding the compound 5b, the KD against p300 was of 3.05 x 10-6 
while the one reported against pCAF was of 1.52 x 10-4. 
On the other hand, both 3-oxobutanoates 3a-d and derivatives 6-8, which are 
characterized by the presence of a heteroatom in their aliphatic chains, showed 
negligible interaction. In addition, in agreement with what was previously 
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reported for LoCAMs,62 it was shown that variations in the alkyl chain length 
influenced the binding profile of the tested pentane-2,4-diones 2a-e. In fact, 
their superior (2e) and inferior (2a and 2b) homologues also produced good 
sensorgrams but showed low and/or concentration-independent responses. 
 
 
Figure 3.1.3: Sensorgrams obtained from the SPR interaction analysis of compounds 
2d, 4b, and 5b binding to immobilized p300 (catalytic domain, aa 1284-1673, top row) 
and PCAF (catalytic domain, aa 492-658, bottom row). Each compound was injected 
at four different concentrations (25, 50, 75, and 100 μM).  
 
3.1.1.3 Biochemical Screening: Radiometric Assay 
SPR, used as a filtering method, gives information about the interaction of the 
molecules with targets and explain the modulatory activity, but cannot be used 
to define the potency of molecules. For this reason, the effect of the selected 
derivatives (SPR+) 2c,d, 4a,b, and 5a,b on the catalytic activity of the human 
recombinant acetyltransferase enzymes p300 and PCAF was determined in 
radiometric activity assays, which were performed by Reaction Biology 
Corporation (Malvern, PA, USA), using curcumin and anacardic acid as 
reference compounds. Two negative controls (SPR-, 6b and 8b) were also tested 
to cross-validate the selection method.  
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As shown in Table 3.1.1, all the SPR+ derivatives substantially affected the 
activity of one or both the HAT enzymes. 
 
 
Table 3.1.1: Effects of compounds 2c,d, 4a,b, 5a,b, 6b, and 8b on the activity of p300 
and PCAF. Compounds were tested in 10-dose IC50 mode with threefold serial dilutions 
starting at 100 µM. Data were analyzed with GraphPad Prism software (version 6.0) 
for IC50 curve fits. Enzyme activity percentage was determined at 100 µM with respect 
to DMSO. Histone H3 was used as substrate (5 µM), and [acetyl-3H]acetyl coenzyme 
A (3.08 µM) was used as an acetyl donor.  
 
In particular, pentane-2,4-diones 2c,d induced a marked dose-dependent 
increase in the enzymatic activity of PCAF (HAT activity at 100 µM: 229% and 
389%, respectively; Table 3.1.1), while they did not affect the activity of p300. 
In contrast, malonic acids 4a,b strongly inhibited both enzymes, with IC50 
values in the low micromolar range (1.3 and 1.1 µM, respectively, for p300, and 
50.3 and 21.1 µM, respectively, for PCAF; see Table 3.1.1), which are similar 
to or more potent than the reference compounds (IC50: 6.5 µM and 33.9 µM for 
curcumin and anacardic acid, respectively; Table 3.1.1). Notably, 3-
oxobutanoic acids 5a,b efficiently inhibited p300 (IC50 values of 2.4 µM and 
4.7 µM, respectively) but also caused strong amplification of PCAF enzymatic 
activity in a dose-dependent manner (HAT activity at 100 µM: 346 and 497%, 
respectively; Table 3.1.1). This effect was even more significant than that 
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observed for pentane-2,4-diones 2c,d. In accordance with the SPR experiments, 
the negative controls negligibly affected the enzymatic activity of p300 and 
PCAF (see 6b and 8b in Table 3.1.1).  
3.1.1.4 Evaluation of Cellular Activity 
After the characterization of the enzymatic activity of compounds 2c, 2d, 4a, 
4b, 5a and 5b using a biophysical and a biochemical method, the screening 
approach continued with the aim to evaluate their effect on cells. Cellular assays 
were carried out on three different cell lines, namely human leukemic monocyte 
lymphoma U937 cells and human cervical carcinoma C33A and HeLa cells. 
First, an MTT assay was performed after the treatment with selected derivatives 
to assess the maximum concentration of compounds that could be used without 
significantly affecting cell viability. For solid C33A and HeLa tumor cell lines, 
it was observed no significant decrease in the number of metabolically active 
cells after 24 h of treatment with concentrations up to 200 µM for derivatives 
2c,d and 4a,b and up to 50 µM for compounds 5a,b. 
On the other hand, in the case of the more sensitive U937 cell line (Figure 
3.1.4a), it was registered a significant decrease in cell viability starting from 
lower concentrations of tested compounds (100 µM for 2c,d and 4a,b and 10 
µM for 5a,b, respectively). Therefore, the derivatives were evaluated on U937 
cell line for their effects on the cell cycle. After 24 h of treatment, compounds 
4b, 5a, and 5b were able to arrest the cell cycle in the G1 phase (Figure 3.1.4b). 
In the case of the latter two compounds, this occurred at concentrations as low 
as 10 µM. This result is consistent with the importance of acetylation for control 
of the G1/S transition.
71-74 Under the same conditions, the other derivatives had 
no significant effects on the cell cycle. 
 
 
- 38 - 
 
Figure 3.1.4: Cell viability and cell-cycle analysis in U937 cells by fluorescence-
activated cell sorting (FACS). a) Cell viability was assessed by measuring the 
mitochondrial-dependent reduction of MTT to formazan. b) U937 cells were treated 
with compounds 2c,d, 4a,b, and 5a,b at the indicated concentrations for 24 h, stained 
with propidium iodide, and subjected to flow cytometric analysis to determine the 
distribution of cells in each phase of the cell cycle. Data are reported as the mean ±SD 
of at least three independent experiments. 
 
Finally, the effects of compounds 2d, 4b, and 5b were determined on the 
acetylation levels of specific lysine residues of core histones H3 (K9) and H4 
(K5) in the three cell lines. Cells were incubated for 24 h with vehicle and tested 
with compounds at the indicated concentrations, using as reference compound 
the suberoylanilide hydroxamic acid (SAHA; 5 µM).75 The histone extracts 
were then immunoblotted with antibodies to specific histone acetylation sites 
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(Figure 3.1.5). Consistently with the different patterns of acetylation recently 
described by Garcia and co-workers,76 it was observed that the tested 
compounds differentially affected the H4K5ac and H3K9ac levels in the three 
cell lines. This observation is not surprising, considering that in the cellular 
context, acetyltransferases are similar to other enzymes by not being isolated; 
they participate in complex pathways and actively crosstalk with each other and 
with other proteins. 
Specifically, the effect of pentane-2,4-dione 2d on both markers was negligible 
in U937 cells (Figure 3.1.5, left and middle panels), whereas a decrease was 
observed in both cervical carcinoma cell lines, which was more evident for 
H4K5ac (Figure 3.1.5). Both malonic acid 4b and 3-oxobutanoic acid 5b 
induced a marked decrease in the acetylation of lysine H4K5 in C33A cells 
(Figure 3.1.5, left panel), whereas no appreciable effect on the same marker was 
detected in HeLa cells, and an increase was observed in U937 cells (Figure 
3.1.5). 
In contrast, derivative 4b induced a moderate decrease in the acetylation of 
H3K9 in C33A and HeLa cells (Figure 3.1.5, middle panels), and there was no 
appreciable variation in U937 cells (Figure 3.1.5, middle panel). The compound 
5b induced a decrease in the acetylation of H3K9 in C33A and HeLa cells 
(Figure 3.1.5, middle panels) and a marked increase in the acetylation level in 
U937 cells (Figure 3.1.5, middle panel). As expected, treatment with the 
reference compound SAHA reliably showed a significant increase in the lysine 
acetylation level (Figure 3.1.5). 
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Figure 3.1.5: Western blot analyses performed with compounds 2d, 4b, and 5b at the 
indicated concentrations for 24 h on the acetylation of the specific lysine residues H4K5 
(left column) and H3K9 (middle column) in histone extracts from a) C33A and b) HeLa 
carcinoma cells, and c) U937 leukemic monocyte lymphoma cells. Acetylation was 
detected by immunoblotting with antibodies specific for histone acetylation sites as 
indicated. Total histone H3 was used to check for equal loading. SAHA (5 µM) was 
used as a reference compound. Signals were detected with the ImageQuant LAS 4000 
digital imaging system and quantified by ImageQuantTL software (version 8.1); total 
histone H3 levels were used for normalization. The results are reported as the mean 
±SD of three independent experiments. 
 
The differences observed in the activity profile of the structurally related 
compounds 2c,d, 4a,b, and 5a,b against the two acetyltransferases could have a 
number of explanations, and the mechanisms underlying their biological effects 
remain unclear. However, it has been previously reported that small 
modifications in structurally related compounds lead to dramatic differences in 
terms of selectivity between PCAF and p300.15 Moreover, is worth mentioning 
that the catalytic mechanisms of the two enzymes are different, with PCAF 
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using a ternary complex mechanism,77 and a Theorell–Chance “hit and run” 
model proposed for p300.19  
In conclusion, the application of this screening strategy allowed the 
identification of some analogues of SPV106 (2d, 4b, and 5b) characterized by 
different activity profiles against PCAF and p300 (pure PCAF activator, pan-
inhibitor, or mixed PCAF activator/p300 inhibitor). The compounds described 
may be useful chemical tools for mechanistic studies of lysine acetylation and 
its implications in physiological and/ or pathological processes.7 
 
3.1.2 From Garcinol to 5-Benzylidenebarbituric Acid Derivatives 
As exemplified by the discovery of SPV106, structural simplification represents 
a drug design strategy to simplify the structure and shorten synthetic routes 
while keeping or enhancing the biological activity of a natural bioactive 
compound.62, 63, 78  
Prompted by these successful results, we decided to apply a molecular pruning 
approach to the molecular scaffold of garcinol that is a non-selective inhibitor 
of p300 extracted from Garcinia Indica. From this compound, in the last few 
years, two molecules have been developed. Isogarcinol and its derivative LTK-
14 are two semisyntethic garcinol derivatives that, even if characterized by 
improved potency and selectivity, they still retain the synthetic complexity of 
garcinol that limits studies on structure-activity relationships. 
To rapidly gain access to the compounds and promptly achieve a comprehensive 
SAR framework, the lead structure of garcinol was simplified step-by-step to 
identify the minimal structural elements required for p300 inhibitory activity.  
Our molecular simplification strategy applied to the garcinol structure is 
schematically depicted in Figure 3.1.5.  
First, the pruning of the condensed cyclohexanone ring turned the bicycle core 
into the simple cyclohexanetrione. Then the isosteric replacement of nitrogen 
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for carbon provided the easily synthesizable barbituric acid moiety, providing 
the first series of analogues (compounds of type A in Figure 3.1.5). The removal 
of the benzoyl carbonyl group and the introduction of unsaturation yielded the 
second (B) and third (C) series of derivatives, respectively. Subsequently, we 
decided to explore the importance of the nature of the carbon chain on the two 
nitrogen atoms and the significance of the substitution pattern on the phenyl 
ring. Therefore, we introduced an aliphatic saturated (i-butyl), unsaturated 
(allyl), or aromatic (benzyl) chain in place of the prenyl substituent on the 
nitrogens, whereas the phenyl ring was decorated with hydroxyl and/or 
methoxyl groups. 
The three series of derivatives resulting from this approach, namely 
benzoylbarbiturates A, benzylbarbiturates B, and benzylidenebarbiturates C 




Figure 3.1.5: Flowchart of the molecular pruning approach. 
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3.1.2.1 Biochemical Screening: Radiometric Assay 
First, a biochemical filter was applied: the effect on the catalytic activity of the 
human recombinant acetyltransferase enzymes p300 and PCAF was determined 
at a fixed concentration of 100 μM in a radiometric activity assay, using 
curcumin,11 anacardic acid,9 and C64614 as reference compounds (the 
radiometric assays were performed by Reaction Biology Corporation, Malvern, 
PA, USA). The results, reported in Table 3.1.2, are summarized as heat maps in 
Figure 3.1.6. Firstly, it was clear that derivatives of the general structure C 
(Figure 3.1.6) were endowed with the highest inhibitory activity against p300: 
they displayed a greater than 90% inhibition of p300 activity, and therefore IC50 
values were determined only for these compounds (Table 3.1.2). 
In addition, the activity was markedly affected by the nature of the substituent 
on the nitrogen atoms. In fact, derivatives with benzyl substituents were always 
more active than the corresponding iso-butyl-substituted analogues and even 
more active than the allyl-substituted ones (compare, for example, the activity 
of compounds 15b and 15c with those of derivatives 16b and 16c and 17b and 
17c, respectively). With regard to the substitution pattern on the phenyl ring, the 
presence of a 4- hydroxyl substituent was crucial for the inhibitory potency of 
the compounds, which was further increased by the presence of a second oxygen 
atom in position 3. In fact, derivative 15b resulted in more potency than 
curcumin and derivatives 15c and 15e were more potent than both curcumin and 
C646 (Table 3.1.2). On the contrary, replacement of the 4-hydroxyl with a 
methoxyl group reduced the activity of the resulting derivatives (compare the 
activities of compounds 15b, 15c, and 15e with those of compounds 15g, 15d, 
and 15f, respectively). It is noteworthy that the inhibition activity was selective, 
as all the compounds were scarcely active against PCAF (Table 3.1.2). 
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Table 3.1.2: Effects of Compounds 9-17 on the Activity of p300 and PCAF. Enzyme 
activity percentage determined at 100 µM with respect to DMSO. Values are the means 
± SD determined for at least two separate experiments and are indicated in percentage 
points. Histone H3 was used as substrate (5 µM), and [acetyl-3H]acetyl coenzyme A 
(3.08 µM) was used as an acetyl donor. The most active compounds were tested in 10-
concentration IC50 mode with 3-fold serial dilutions starting at 100 μM. Data were 







Figure 3.1.6: Inhibitory activities of compounds 9-17. The heat maps depict the 
percentage of inhibition of p300 activity at 100 μM concentration of compounds 9-17 
(top panel) and the IC50 values for selected compounds 15-17 (bottom). 
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3.1.2.2 Biophysical Screening: Surface Plasmon Resonance Assay 
The biochemical assay allowed the selection about 20 compounds that were able 
to inhibit selectively p300. To further characterize the activity of the selected 
compounds and establish whether their inhibitor effects were due to direct 
binding to the target protein, SPR biophysical assay were performed. This assay 
was applied to Benzylidenbarbituric acid derivatives 15-17 (for which the IC50 
was measured), together with compounds 9a and 12a, chosen as the best 
inhibitors among the benzoylbarbiturates A and the benzylbarbiturates B, 
respectively (Figure 3.1.6). Toward this aim, the human recombinant p300 (aa 
1284-1673) catalytic domain was immobilized (up to approximately 10000 RU, 
response units) on a sensor chip, and tested ligands were injected at different 
concentrations over the protein surface, following the procedure reported in 
Chapter 3.1.1.2. 
All compounds were shown to interact with the immobilized recombinant p300 
HAT domain, even if a KD measurement was possible only for derivatives 12a 
(KD = (1.1 ± 0.7) × 10−6) and 9a (KD = (2.4 ± 1.3) × 10−7). For the 
benzylidenebarbituric inhibitors of type C, while setting up the injection 
conditions, an unexpected SPR response for subsequent injections at the same 
concentration was observed. Specifically, all derivatives gave a high SPR signal 
for the first injection immediately after dilution from the stock solution in 
DMSO (the time passed from the dilution to the real contact of the molecule 
with the sensor chip was estimated to be 2 min), while subsequent injections of 
the same dilution (after 10 and 15 min) gave a strongly reduced signal. On the 
other hand, a fresh dilution from stock produced, again, a high signal 
superimposable on the first injection.  
The SPR response of compound 15b binding, taken as representative of the 
series, to immobilized p300 is shown in Figure 3.1.7, whereas all the other 10 
sensorgrams are displayed in Figure 3.1.8. 
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Figure 3.1.7: Sensorgrams obtained from subsequent injections (after 2, 10, and 15 
min) of a 10 μM solution of compound 15b on immobilized p300 (catalytic domain, aa 
1284-1673). 
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Figure 3.1.8: Sensorgrams obtained from subsequent injections (after 2, 10, and 15 
min) of a 10 μM solution of compounds 15c-g, 16b-e and 17e on immobilized p300 
(catalytic domain, aa 1284-1673). 
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3.1.2.3 Stability assays 
The time-dependent outcomes of the SPR prompted the evaluation the stability 
of the barbituric acid derivatives in aqueous solution. Therefore, compounds 
15b-g, as well as derivatives 9a and 12a, were incubated with phosphate-
buffered saline (PBS) solution at 25 °C and the stability of compounds was 
evaluated by HPLC analysis after 2, 10, 30, 60 min and 24 h (Figure 3.1.9). The 
experimental results indicated that the 5-benzoyl- and 5-benzylbarbituric acid 
derivatives 9a and 12a, respectively, were stable under the conditions routinely 
used in the biological assays (Figure 3.1.9). On the other hand, as hypothesized, 
the 5-benzylidenebarbituric acid derivatives, while stable in organic solvents, 
were revealed to be unstable in aqueous solutions. For almost all the 
compounds, degradation became evident after 10 min of incubation in an 
aqueous medium, and after 24 h, only the presence of hydrolysis products 
(aldehyde and barbituric acid) was detected. The effect was especially marked 
for derivatives bearing a hydroxyl group in the phenyl ring, for which 
degradation was almost complete after only 30 min of incubation in the aqueous 
medium (15b-e, Figure 3.1.9). 
These findings, which are consistent with the SPR results, suggested that the 
IC50 values provided by the biochemical assays might have underestimated the 
potency of the 5-benzylidenebarbituric acid derivatives. The high susceptibility 
of benzylidenebarbituric derivatives of type C to hydrolysis appeared as a major 
issue to be addressed before considering any further studies, considering the 
incompatibility of the stability conditions with all biological assays. Therefore, 
we resolved to modify their structure to overcome the aqueous instability 
problem while preserving the activity of the parent compounds.  
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Figure 3.1.9: HPLC chromatograms obtained for compounds 15b-g, 9a and 12a 
injected immediately after the dissolution in PBS, after 2, 10, 30, 60 min and 24 h. 
Spectra were recorded at 220 nm. 
 
3.1.2.4 Chemical Stabilization of 15b Derivative 
We supposed that the insertion of two methyl groups in the ortho positions of 
the benzylidene moiety of derivative 15b, one of the most potent compound 
designed, could protect the double bond from hydrolysis. As the crucial 4-
hydroxyl group was not involved, this modification was expected to not 
significantly affect the inhibitory potency. 
Hence, in the EMCL the derivative 15h was synthesized and its chemical 
stability was first evaluated. HPLC analysis revealed that the compound did not 
decompose after exposure to PBS buffer solution over a period of 24 h (Figure 
3.1.10).  
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Figure 3.1.10: Chemical structure of derivative 15h and HPLC chromatograms 
obtained for it, injected immediately after the dissolution in PBS, after 2, 10, 30, 60 
min and 24 h. Spectra were recorded at 220 nm. 
 
3.1.2.5 Biochemical and Biophysical Characterization of 15h Derivative 
Once chemical stability was established, derivative 15h was tested for inhibition 
of the recombinant acetyltransferase enzymes p300, PCAF and GCN5 (Figure 
3.1.11). It was found that the introduction of two methyl groups in the structure 
of 15b resulted in an analogue (derivative 15h) endowed with potency and 
selectivity comparable to those of the parent compound. In fact, 15h efficiently 
inhibited p300 (IC50 value of 2.9 µM) while being practically inactive against 
the enzymes GCN5 and PCAF.  
 
Figure 3.1.11: Concentration-response inhibition of p300, GCN5 and PCAF by 
compound 15h. The compound was tested in 10-concentration IC50 mode with 3-fold 
serial dilutions starting at 100 μM. Data were analyzed using GraphPad Prism software 
(version 6.0) for curve fitting, using a sigmoidal concentration-response with a variable 
slope equation. 
 
It is important to note that, due to the time-dependent instability of aqueous 
solutions of 5-benzylidenebarbiturates 15b-g, a direct comparison of the 
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acetyltransferase inhibitory potency of compound 15h with those of derivatives 
15b-g might not be very meaningful.  
After the biochemical characterization of 15h derivative, to establish whether 
its inhibitor effect was due to direct binding to the target protein, the SPR 
biophysical assay was performed. As shown in Figure 3.1.12, the concentration-
dependent responses and the clearly evident exponential curves during both the 
association and dissociation phases indicate that 15h derivative efficiently 
interacts with the protein.  
 
Figure 3.1.12: Sensorgrams obtained from the SPR interaction analysis of compound 
15h to immobilized p300 (catalytic domain, aa 1284-1673, top row). Compound was 
injected at 0.5, 1, 5, and 10 μM, giving the concentration-dependent signals shown. 
Using the 1:1 Langmuir binding fit model of the BIAevaluation software, the KD was 
determined. (KD = 6.27 ± 1.1 x 10-8). 
 
The conjugated double bond in compound 15h is potentially electrophilic and 
could serve as a Michael acceptor and covalently modify the target enzyme. 
Therefore, even if the results of the SPR experiments were not consistent with 
this hypothesis, it was investigated whether 15h could generate adducts with the 
nucleophile β-mercaptoethanol. HPLC chromatographic analysis revealed no 
evidence of reaction under the buffer conditions used in the enzymatic assay 
(Figure 3.1.13), thus suggesting that 15h acts as a reversible p300 inhibitor. 
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Figure 3.1.13: HPLC chromatograms of the mixture of compounds 15h and 2-
mercaptoethanol (β-mercaptoethanol, BME) injected immediately after the dissolution 
in PBS, after 30, 60, 120, 240 min and 24 h. Spectra were recorded at 220 nm. 
 
3.1.2.6 Inhibition Mechanism of 15h Derivative 
Subsequently, to better characterize the enzymatic activity of compound 15h, 
the kinetic mechanism of p300 inhibition was evaluated using another 
biochemical method, the AlphaLISA homogeneous proximity immunoassay. 
This type of assay allows one to measure enzyme activity by detecting the 
acetylation of a biotinylated histone H3 peptide using streptavidin-coated donor 
beads and AlphaLISA acceptor beads conjugated to an antibody directed against 
the modified substrate.  
The inhibitory effect of 15h was explored by performing two sets of 
experiments. Firstly, enzyme activity was measured by varying the histone H3 
peptide substrate concentration while keeping the acetyl-CoA concentration 
constant. Subsequently, the acetyl-CoA concentration was varied while keeping 
the H3 peptide concentration constant.  
Figure 3.1.14 shows the double-reciprocal plots at three different inhibitor 
concentrations (0, 5, and 10 μM). From these data, derivative 15h was shown to 
be a non-competitive inhibitor versus both acetyl-CoA and a histone H3 peptide, 
able to bind both the free enzyme and the enzyme-substrate complex, even with 
unequal affinity constants determined by the two secondary plots reported in 
Figure 3.1.15.  
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Figure 3.1.14: (A) Plot of 1/v vs 1/[H3] at a fixed acetyl-CoA concentration (3 μM) 
and three different concentrations of 15h shows non-competitive inhibition. 15h Ki = 
9.4 μM, α Ki = 6.8 μM, H3 apparent Km = 30 nM. (B) Plot of 1/v vs 1/[acetyl-CoA] at 
a fixed H3 concentration (0.05 μM) and three different concentrations of 15h shows 
non-competitive inhibition. 15h Ki = 2 μM, α Ki = 5.7 μM, acetyl-CoA apparent Km 




Figure 3.1.15: Kinetic assays. (A, C) The slope of the double reciprocal plot was 
plotted against inhibitor concentration ([I] in μM). Ki was obtained from the negative x 
intercept of the slope replot. A (H3) Ki= 9,4 µM, C (AcetylCoA) Ki= 2 µM. (B, D) The 
reciprocal of Vmax was plotted against inhibitor concentration ([I] in μM). αKi was 
obtained from the negative x intercept. B (H3) αKi= 6,8 µM, D (AcetylCoA) αKi= 5,7 
µM. 
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3.1.2.7 Evaluation of Cellular Activity 
After the identification of the stable, potent and selective p300/CBP inhibitor 
15h, its effect was evaluated in cells. Before starting with cellular assays, it was 
estimated the cell permeability of 15h.  
To this aim, the well-validated parallel artificial membrane permeability assay 
(PAMPA) technique was employed.79, 80 The highly permeable drug propranolol 
and the poorly permeable drug furosemide were used as references. The 
compound showed an apparent permeability value (Papp) of 1.9 × 10
−6 cm/s, 
similar to that of propranolol (Papp = 4.1 × 10
−6 cm/s), and very different from 
furosemide (Papp = 0.09 × 10
−6 cm/s).  
These positive findings prompted the evaluation on the effect of 15h on cells. 
Similarly to what was carried out in the previously reported SPV106 analogues 
screening, it was evaluated the effect of 15h on the cell cycle progression and 
the percentage of sub-G1 hypodiploid nuclei in the human leukemia U937 cell 
line. After 72 h of incubation with 15h at 100 μM, the compound induced a 
marked arrest in the G0/G1 phase and a significant increase in hypodiploid nuclei 
percentage (Figure 3.1.16). 
 
Figure 3.1.16: Cell cycle analysis (A) and percentages of cells with hypodiploid nuclei 
(B) in U937 cells by fluorescence-activated cell sorting (FACS). The U937 cells were 
treated with the compounds 15h and garcinol at the indicated concentrations for 72 h, 
stained with propidium iodide, and subjected to flow cytometric analysis to determine 
the distribution of cells in each phase of the cell cycle. Data are reported as the mean ± 
SD of at least three independent experiments. 
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Subsequently, the effects of compound 15h on cellular histone acetylation were 
investigated, using modification-specific antibodies against H3K9ac and 
H4K5ac (Figure 3.1.17). Cells were incubated for the indicated times (24, 48, 
or 72 h) with 15h (100 μM) or the reference compound garcinol (5 μM),10 and 
the histone extracts were then immunoblotted with antibodies to specific histone 
acetylation sites. As represented in Figure 3.1.18, it was observed that 
compound 15h induced a marked and time-dependent reduction in the 




Figure 3.1.17: Western blot analyses performed with compound 15h at 100 μM for 24, 
48, and 72 h on the acetylation of the specific lysine residues H4K5 (upper lane) and 
H3K9 (middle lane) in histone extracts from U937 leukemic monocyte lymphoma cells. 
Acetylation was detected by immunoblotting with antibodies specific for histone 
acetylation sites as indicated. Total histone H3 was used to check for equal loading. 
Garcinol (5 μM) was used as a reference compound. 
 
Taken together, all these findings corroborate the inhibitory effect of 15h on the 
intracellular histone acetylation mediated by p300 and are consistent with the 
importance of this enzyme for control of the G1/S transition. In fact, p300 is 
required for the orderly G1/S transition in human cancer cells, and selective 
inhibitors, such as C646, induce cell cycle arrest in the G1 phase and 
apoptosis.14, 71, 81-83 
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In conclusion, this screening method allowed the discovery of the derivative 
15h, more potent and selective than the reference compounds curcumin and 
anacardic acid; it is a reversible inhibitor and non-competitive versus both 
substrate and cofactor, endowed with good cell permeability (Papp = 1.9 × 10
−6 
cm/s), as assessed by the PAMPA technique. Furthermore, in human leukemia 
U937 cells, it induced a marked and time-dependent reduction in the acetylation 
of lysine H4K5 and H3K9, a marked arrest in the G0/G1 phase and a significant 
increase in hypodiploid nuclei percentage.  
Therefore, 15h may be an invaluable chemical probe not only for mechanistic 
studies of p300-mediated lysine acetylation but also to further investigate the 
biological role of this KAT enzyme and its implications in physiological and/or 
pathological processes.8 Moreover, in the last few months, compound 15h 
became commercially available (Xcessbio™) and was recently used in a 
research article of Simola D. F. et al. as CBP/p300 in vivo chemical probe to 
study the synaptic plasticity in the ant Camponotus floridanus.84 
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3.2 SETD8 
SETD8 is the sole protein lysine methyltransferase (PKMT) known to 
monomethylate lysine 20 of histone H4 in vivo (Chapter 1.2.2.2.1). As SETD8 
is implicated in many essential cellular processes, the identification of specific 
modulators is of great importance to further clarify the biological role of this 
methyltransferase. Despite such need, few modulators of high quality have been 
reported so far for SETD8.29, 85 
A few years ago, a high-throughput screening campaign of ChemBridge’s 
diversity library (DIVERSet, 10000 compounds) led Bedford and coworkers to 
the identification of small molecule modulators of protein methyltransferases.86 
On the basis of our observation that two different dye-like scaffolds, namely a 
xanthenic moiety and an aminohydroxynaphthalene sulfonic moiety, were 
recurrent as privileged structures in the hits selected, in the EMCL a small 
focused library containing the two dye-like scaffolds was prepared to identify 
hits for the development of modulators of arginine methyltransferases 
(PRMTs).70, 87, 88  
Interestingly, a few compounds were able to inhibit both arginine and lysine 
methyltransferases and among them, the compound EPI-009 (Thymolphthalein) 
(Figure 3.2.1) showed low IC50 values against SETD8 (IC50= 9 μM) in a 
radioactive assay.89  
 
 
Figure 3.2.1: EPI-009 structure. 
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To further investigate its activity profile and with the aim to develop selective 
SETD8 inhibitors, a screening approach for this epigenetic enzyme was 
developed. 
3.2.1 His-SETD8-FLAG expression and purification 
The development of different biochemical and biophysical assays requires large 
amount of protein. To reduce the costs of the assays, the first issue to be 
addressed was the “in house” production of SETD8. Therefore, a pET-28 b (+) 
vector containing SETD8 (residues 51-383) was generously provided by Dr. D. 
Reinberg (Department of Biochemistry and Molecular Pharmacology, Howard 
Hughes Medical Institute, New York (USA)) and allowed the expression of a 
double tagged His-FLAG human SETD8 protein. The vector was transformed 
into BLR(DE3)pLysS competent cells and the protein was overexpressed in LB, 
optimizing the induction conditions at 1 mM IPTG for 6 h at 25 °C. The 
expressed protein was purified by affinity chromatography using an AKTA 
FPLC system and a 1-mL HisTrap HP column (Figure 3.2.2).  
The activity of the protein was determined in AlphaLISA assay, which was 
previously optimized using a commercially available protein (His-SETD8). It 
was not possible to use the expressed SETD8 in the same concentration of the 
commercially available one (20 nM) because of an unsuitable signal/noise ratio. 
It was necessary to increase the concentration of the expressed protein (1 μM) 
to have a result comparable to the one got with the reference protein (Figure 
3.2.3). 
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Figure 3.2.2: 1-7) Elution Fractions. 
SDS-PAGE after the purification of the protein by affinity chromatography using 
HisTrap HP column and an AKTA FPLC at 1 mL/min. 
 
 
Figure 3.2.3: AlphaLISA assay performed with the commercially available His-
SETD8 and the expressed His-FLAG-SETD8. The assay was performed incubating the 
protein with 150 nM of Histone H4 and 200 μM of SAM for 1h at room temperature. 
The results reported are the means ± SD determined for at least two separate 
experiments. 
 
3.2.1.1 Microscale Thermophoresis (MST) experiments at LMU  
After the optimization of expression and purification procedures for SETD8, I 
spent a period at Ludwig Maximilians Universität München (LMU) in the lab 
of prof. Axel Imhof, where I had the opportunity to learn the Microscale 
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Thermophoresis technique (MST). MST measurements are based on the 
physical principle of Thermophoresis, which is the directed motion of molecules 
in temperature gradients (Chapter 1.6.3).53, 54  
After the labeling of human His-FLAG-SETD8 with the dye NT-647, the 
protein was used to perform Thermophoresis experiments in order to study the 
interaction of the protein with EPI-009. Unfortunately, these experiments did 
not allow the detection of any interaction between the protein and the small 
molecule compound (Figure 3.2.4). 
 
 
Figure 3.2.4: Microscale Thermophoresis time-traces of the interaction between 
human His-FLAG-SETD8 and EPI-009. The overlapping of curves showed no 
interaction between the two binding partners. 
 
However, the thermophoresis experiments performed under the same conditions 
but using another protein, a mouse-SETD8 without any tag (characterized by 
91% sequence homology compared to the human one) showed a clear 
interaction with EPI-009, with a KD of 1.02 x 10-4 (Figure 3.2.5).  
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Figure 3.2.5: Microscale Thermophoresis time-traces of the interaction between mouse 
SETD8 and EPI-009.  
 
The different behaviour of the two proteins let us to speculate that tags could 
prevent the binding with the small molecule EPI-009. It is worthwhile noting 
that all tags, whether large or small, could interfere with the biological activity 
of a protein, impede its crystallization, interfere with the proper structure or 
otherwise influence its behaviour. Consequently, it is usually desirable to 
remove them and work with a protein in a native state.90-93 Unfortunately, in the 
case of this protein, the removal of both tags was not possible because of the 
lack of cleavage sites.  
 
3.2.2 Cloning, Expression and Purification of GST-SETD8 
With the aim to obtain a protein in a native state, the DNA sequence encoding 
for human SETD8 was cloned into a pGEX-4T-1 plasmid, in order to express a 
cleavable GST-tagged protein at the amino terminus.  
The plasmid pET-28 b (+) was sequenced, afterwards primers were designed to 
amplify the DNA encoding for the protein. After the amplification by PCR 
reaction, the DNA was inserted first in the cloning vector pGEM-T and then in 
the expression vector pGEX-4T-1, using as restriction sites BamHI and XhoI. 
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The vector pGEX-4T-1 was transformed into BLR(DE3)pLysS competent cells 
and the protein was overexpressed in LB, optimizing the induction conditions 
at 1 mM IPTG for 2 h at 37 °C. The expressed protein was purified by affinity 
chromatography using an AKTA FPLC system and a 1-mL GSTrap HP column 
(Figure 3.2.6). Unfortunately, the protein showed instability during the 
purification steps. As reported in Figure 3.2.5, GST-SETD8 (66 kDa) was eluted 
together with some degradation products. Despite the highlighted instability, the 




Figure 3.2.6: SDS-PAGE of the purification of GST-SETD8 (66 kDa) by affinity 
chromatography using GSTrap HP column and an AKTA FPLC at 1 mL/min. Lane 1: 
lysate; Lane 2: unbound fraction; Lanes 3-8: elution fractions 
 
As shown in the Figure 3.2.7, the expressed GST-SETD8 (3.3 μg/mL) was 
active in the biochemical assay. 
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Figure 3.2.7: AlphaLISA assay performed with the commercially available His-
SETD8 and the expressed GST-SETD8. The assay was performed incubating the 
protein with 150 nM of Histone H4 and 200 μM of SAM for 1h at room temperature. 
The results reported are the means ± SD determined for at least two separate 
experiments. 
 
3.2.2.1 Cleavage of GST tag 
Subsequently, GST cleavage was performed using the ThrombinCleanCleavage 
Kit. A specific cleavage site located between the tag and the protein sequence 
would have ensured simple removal of the tag. 
Tags cleavage conditions are dependent on the protein of interest and have to be 
optimized for each protein separately. In the case of GST-SETD8, although 
different temperatures and incubation times were tested (data shown in Table 
3.2.1), it was not possible to isolate the cleaved protein because of protein 
degradation or inactivity of the proteolytic enzyme. Therefore, also this 
approach has been abandoned.  
Indeed, the use of Thrombin to obtain a pure “native-like” protein of interest is 
often associated to non-specific cleavage: even if the most common linker 
sequence recognized by thrombin is LVPRG or LVPRGS (which is derived 
from the sequence in bovine factor XIII that is cleaved by thrombin during the 
activation process), it is not absolute.43, 44 Cleavage can occur at other sequence 
sites in the protein, causing proteolytic degradation and this was probably the 
case of GST-SETD8. 
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In order to obtain a stable and easily cleavable protein, it was selected the 
Halotag system, that was developed to overcome the current limitations of 
traditional protein tagging platforms.94 Experiments on the optimization of 
expression and purification conditions of SETD8 with the Halo tag are still in 
progress. 
 
Table 3.2.1: Summary of all the tested GST cleavage conditions. 
 
3.2.3 Gene Reporter System 
For the development of a robust screening platform for SETD8, biochemical 
and biophysical approaches were needed as well as cellular assays. 
To address this need, the experimental conditions of a Gene Reporter System  
(previously reported by D. Reinberg and coworkers28) have been optimized.  
Using a 293T-REx cell line containing a stably integrated 5xUAS site directing 
luciferase expression, GAL4-SETD8 was expressed under an inducible 
tetracycline-responsive promoter. In normal conditions, Tet repressors bound to 
TetO2 elements keep Gal4-SETD8 expression repressed. Upon induction by 
tetracycline, the repressors leave the DNA and GAL4-SETD8 is expressed, 
resulting in binding to the GAL4 binding sites to the luciferase reporter that is 
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stably integrated in euchromatic DNA. SETD8 recruitment to the artificial UAS 
locus led to decrease in luciferase expression, due to the methylation on the gene 
promoter by SETD8 (Figure 3.2.8). The decrease of luciferase expression can 
be easily monitored by a luciferase activity assay (Dual-Light® luminescent 
reporter gene assay).  
 
Figure 3.2.8: Gene Reporter System 
 
The experimental conditions of the assays were optimized in order to obtain the 
transfection of plasmid in cells, detectable by luciferase activity variation. First, 
the required cell confluence was evaluated: 3000-5000-10000 cells were seeded 
in 96-well plate and after 48 h of incubation at 37 °C it was shown that the better 
confluence was obtained by seeding 10000 cells for each well. Subsequently, 
several transfection experiments were performed in order to establish the 
minimum concentration of transfecting agent needed: while the use of 0.1 
μL/well of Lipofectamine was not sufficient for the transfection, good results 
were achieved using 0.2 and 0.4 μL of transfecting agent; accordingly, 0.2 μL 
of Lipofectamine was used in the following experiments. Finally, the quantity 
of vector to be used in the experiments was evaluated: among 100, 50 and 25 
ng of DNA, the best results were achieved using 100 ng of pcDNA™4/TO 
GAL4-SETD8. 
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In Figure 3.2.9 the result of the luciferase assay, performed with the optimized 
transfection conditions, is reported. As expected, the addition of Tetracycline, 
which led to overexpression of GAL4-SETD8, is associated with a decrease in 
Luciferase expression, detected in a luminesce assay. The use of this system will 
be particularly useful, as it will allow the identification of new cell-permeable 
modulators of SETD8. 
 
Figure 3.2.9: Dual-Light® Luminescent Reporter Gene Assay performed on 293T-
REx lysate after the transfection. 
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3.3 TUDOR DOMAINS OF PHF20 
3.3.1 UNC1215 analogues as Tudor modulators 
Among different reader proteins, Tudor domains of PHF20 belong to the Royal 
superfamily of methyl-lysine effector proteins (Chapter 1.4.2.1.1). 
UNC1215 (Figure 3.3.1) is the first in class chemical probe for the reading 
function of L3MBTL3, a relatively uncharacterized member of the human 
Malignant Brain Tumor (MBT) family of chromatin interacting transcriptional 
repressors. Interestingly, this is the only molecule described to interact with the 
Tudor domain of PHF20.95 With the aim to discover new potent and selective 
inhibitors of this epigenetic reader, a small pool of UNC1215 analogues was 
synthesized in the EMCL (for patent reasons, I cannot show the structures of the 
prepared derivatives). In order to evaluate the activity of these putative 
modulators of this reader, a screening method for this target was established.  
 
Figure 3.3.1: UNC1215 structure. 
 
3.3.1.1 Protein expression and purification 
Since Tudor domain of PHF20 is a newly identified target, the protein is not 
commercially available. A pGEX-4T-1 vector containing Tudor 1 and 2 
(residues 1-150) was generously provided by Dr. M. Bedford (Department of 
Epigenetics & Molecular Carcinogenesis, Smithville, Texas, USA) and allowed 
the expression of a GST-tagged protein (Figure 3.3.2).  
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Figure 3.3.2: Plasmid map for the expression of PHF20 Tudors (aa 1-150) as GST 
tagged protein (44 kDa).  
 
The vector was transformed into BLR(DE3)pLysS competent cells and the 
protein was overexpressed in LB, optimizing the induction conditions at 1 mM 
IPTG for 4 h at 37 °C. The expressed protein was purified by affinity 
chromatography using an AKTA FPLC system and a 1-mL GSTrap HP column 
(Figure 3.3.3).  
 
Figure 3.3.3: SDS-PAGE of the purification of the protein by affinity chromatography 
using GSTrap HP column and an AKTA FPLC at 1 mL/min. Lane 1: lysate; Lane 2: 
unbound fraction; Lanes 3-11: elution fractions. 
 
With the aim to obtain the protein free from its fusion carrier partner, the GST 
tag was completely cleaved using the ThrombinCleanCleavage Kit (Figure 
3.3.4). After the cleavage, the purification of the native protein was performed 
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by ionic exchange chromatography using a Mono Q column, taking advantage 
of their different isoelectric points (Figure 3.3.5). 
 
Figure 3.3.4: 1: SDS-PAGE after the GST cleavage, which was performed incubating 
the protein with Thrombin beads for 6 h at room temperature. Lane 1: protein before 
the cleavage; Lane 2: protein after the cleavage. 
 
Figure 3.3.5: SDS-PAGE of the separation of the protein from GST by anionic 
exchange chromatography using a Mono Q column. Lanes 1-2: protein; Lanes 3-4: 
GST. 
 
3.3.1.2 Biophysical Screening: nanoDSF 
The cleaved protein was used in a biophysical assay with the aim to evaluate the 
interaction with UNC1215 analogues. This primary screening was performed 
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by nanoDSF that is an advanced Differential Scanning Fluorimetry method for 
measuring ultra-high resolution protein stability (Chapter 1.6.2).   
All compounds were screened by nanoDSF at 100 μM concentration and if they 
exhibited a ΔTm ≥ 0.5 °C (chosen as cut-off), they were selected as potential 
modulators. Therefore, compounds EML637, EML639, EML644 and EML666 
met the selection criteria exhibiting ΔTm values ranging from 0.5 - 1.1 °C at 
100 μM (Table 3.3.1). 
 
 
Table 3.3.1: nanoDSF assays were performed using the Prometheus. The small 
molecule screening was performed at the fixed dose of 100 µM, with a protein 
concentration of 20 µM. For the analysis, standard capillaries were used. 
 
3.3.1.3 AlphaScreen assay: design, optimization and evaluation of UNC1215 
analogues activity 
In order to analyse the effect of UNC1215 analogues on the reader activity of 
Tudor domains of PHF20, an AlphaScreen assay was designed and set-up using 
streptavidin-coated donor beads and anti-GST antibody coated acceptor beads 
to measure binding of a GST-tagged protein to a biotinylated histone peptide.  
With the aim to define the best conditions under which the assay delivered a 
high signal and low background, different buffer components were tested; first, 
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the impact of three detergents (Tween20, Triton-X100 and CHAPS) on assay 
signal was examined (Figure 3.3.6).  
 
Figure 3.3.6: Effect of three detergents to decrease the nonspecific binding observed 
when the assay was performed in basic buffer 20 mM Tris-HCl pH 8. Each assay was 
performed in presence of NaCl 50 mM. The use of Tween 20 resulted in the best 
signal/noise ratio. 
 
The use of Tween 20 yielded the best signal/background ratio, so this detergent 
was subjected to a 3-point titration to determine its optimal concentration in the 
assay buffer; in the same assay, 3 different concentration of NaCl were tested 
as well. Two combinations of reagents yielded similar profiles: NaCl 50 mM 
with Tween20 0.025% and NaCl 25 mM with Tween 0.05% (Figure 3.3.7).  
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Figure 3.3.7: Optimization of the components for the assay buffer in order to facilitate 
the desired interaction between the binding partners. Tween 20 and NaCl were each 
titrated over 3 concentration points, and the relative effect, defined as the signal-to 
background window, is plotted. 
 
To reduce assay background, the effect of 0.1% BSA in the two selected buffer 
was tested. As the addition of BSA caused no significant change in assay signal 
and the combination of 25 mM NaCl with 0.05% Tween 20 showed a slightly 
better ratio, these conditions were selected for subsequent experiments (Figure 
3.3.8). 
 
Figure 3.3.8: Effect of BSA and optimization of Tween20 and NaCl in the optimized 
assay buffer. 
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After the optimization of the assay buffer, the first experiment performed was a 
protein cross-titration in order to determine optimal concentrations of enzyme 
and substrate for the assay. In this experiment, while the concentrations of beads 
were kept constant, the concentration of the binding partners varied: GST-
protein and H4K20me2 were titrated from 0 to 100 nM and 0 to 200 nM, 
respectively (Figure 3.3.9).  
A hook point was reached at 100 nM H4K20me2, after which the signal begins 
to decrease because the protein concentration surpasses the binding capacity of 
the beads: determining where high concentrations of analyte lead to non-
productive binding and loss of signal is essential in the optimization of 
AlphaScreen assays. The best signal/noise ratio was achieved using protein 25 
nM and the substrate 100 nM so these concentrations were selected for further 
optimization and validation.  
 
Figure 3.3.9: Cross-titration data for Tudors binding to biotinylated H4K20me2 
peptide, using Streptavidin Donor Beads and anti-GST Acceptor beads. 
 
Finally, a time course for protein-substrate interaction was performed to 
establish the optimal incubation time; anti-GST Acceptor beads were added 
after 30, 60 and 120 min. Because of the better signal/noise ratio, a 120 min 
interaction time was selected for all subsequent experiments (Figure 3.3.10). 
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Figure 3.3.10: Time dependence of the Alphascreen signal. Three incubation times 
were examined: 30, 60 and 120 minutes. 
 
After the optimization of assay conditions, this assay was used to evaluate the 
effect of UNC1215 analogues on Tudor domain reader activity; compounds 
activity was determined at a fixed concentration of 100 μM. As reported in 
Figure 3.3.11, the four molecules (EML637, EML639, EML644 and EML666), 
which were positive in the nanoDSF screening, were endowed with inhibitory 
activity ≥ 80%, confirming the validity of the nanoDSF biophysical assay as 
primary screening. Experiments are still in progress to evaluate the IC50 of these 
compounds, as well as to characterize in more details their inhibition 
mechanism.
 
Figure 3.3.11: Effects of Compounds on the Activity of Tudor domains. Enzyme 
activity percentage determined at 100 µM with respect to DMSO. 
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Furthermore, the compound EML638, which did not cause a marked variation 
of the Tm measured in the nanoDSF experiments, strongly inhibited the reader 
activity of the protein in the Alphascreen assay. This compound could behave 
as a false negative in nanoDSF assay or a false positive in Alphascreen assay. 
Experiments are in progress to evaluate the real activity of this compound, 
which remains unclear and should be addressed. 
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4. CONCLUSIONS 
 
It is widely reported that epigenetic proteins are involved in the development of 
several human diseases, with different mechanisms of action. Inhibitors of two 
classes of epigenetic enzymes, the DNMTs and HDACs, have already 
demonstrated to be useful chemotherapeutic agents for specific cancers, and 
they are approved drugs for these indications.  
However, the number of reported modulators is limited and refers only to 
specific classes of epigenetic enzymes. As the availability of selective chemical 
probes against individual epigenetic enzymes is necessary for exploring their 
physiological and pathological activities, the lack of specific modulators is 
responsible for a poor knowledge of the biological roles of several epigenetic 
proteins.  
The discovery of epigenetic modulators is affected by several problems. It is 
worth mentioning that these enzymes do not work alone but they participate in 
complex pathways and actively crosstalk with each other and with other 
proteins. Moreover, the lack of specific and robust screening methods to 
evaluate epigenetic enzymes activity get difficult to deeply understand this 
complex network.  
This thesis reported on the application of biochemical and biophysical 
techniques to obtain a multiple screening platform for the study of specific 
epigenetic enzymes. This combined approach has been useful to overcome the 
limitations of each screening technique, allowing the identification and a deep 
characterization (defining potency, selectivity and mechanism of action) of 
several small-molecule modulators synthesized in the EMCL. In particular, 
among the different epigenetic enzymes, this approach was applied to the 
acetyltransferase p300, the methyltransferase SETD8 and the reader domains of 
PHF20. 
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Regarding p300, SPV106 and garcinol were selected as lead compounds. 
Initially, a series of SPV106 analogues was prepared and tested through an SPR-
based filtering procedure to select compounds able to bind the acetyltransferase 
enzymes p300 and PCAF. Subsequently, it was reported that all the SPR+ 
derivatives markedly affected the catalytic activity of one or both enzymes in a 
radiometric assay. Finally, the effect of the most promising compounds was 
evaluated on the acetylation of lysine residues H4K5 and H3K9 in C33A, HeLa, 
and U937 cell lines and on the ability to alter the cell cycle. This approach 
allowed the identification of derivatives 2d, 4b and 5b as modulators of p300 
and PCAF. 
Again regarding p300, the application of a molecular pruning approach to the 
garcinol core structure led to the identification of the barbituric acid moiety as 
a useful scaffold to easily prepare numerous analogues and achieve an inclusive 
SAR framework for p300 inhibition. In this case, the screening platform was 
first characterized by the application of a radioactivity-based assay to measure 
compounds potency, followed by an SPR method that highlighted the instability 
of the most promising compounds in aqueous solution. The chemical 
stabilization of the compound 15b led to the identification of derivative 15h, 
which retains the ability of selectively inhibit p300. Subsequently, it was 
evaluated the kinetic mechanism of p300 inhibition using an AlphaLISA 
homogeneous proximity immunoassay. The derivative 15h was shown to be 
non-competitive versus both acetyl-CoA and a histone H3 peptide. Furthermore, 
in human leukemia U937 cells, it induced a marked and time-dependent 
reduction in the acetylation of lysine H4K5 and H3K9 and a marked arrest in 
the G0/G1 phase. Therefore, the derivative 15h together with the SPV106 
analogues 2d, 4b and 5b, may be used as invaluable chemical probes to further 
investigate the biological role of acetyltransferase enzymes and their 
implications in physiological and/or pathological processes. 
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Regarding the Tudor domains of PHF20, the nanoDSF biophysical assay was 
applied to evaluate the ability of the protein to bind a small pool of UNC1215 
analogues synthesized in EMCL. Afterwards an Alphascreen assay was 
designed and developed for the evaluation of the enzymatic activity of the 
synthesized compounds. The use of these techniques allowed the identification 
of the small-molecule compounds EML637, EML639, EML644, EML666, 
which are able to bind and inhibit Tudor domains of PHF20 and whose activity 
is still under characterization. 
Finally, as regard to the methyltransferase SETD8, the preparation of a protein 
suitable for biophysical and biochemical assays needed more efforts than 
expected. For this reason, the development of a screening approach is still in 
progress. 
In conclusion, this multiple approach proved to be widely usable because of its 
robustness and reliability. The application of this platform would provide new 
opportunities to increase drug discovery success and productivity in the 
epigenetic field. 
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5. MATERIALS AND METHODS 
5.1 Chemistry: Synthesis of SPV106 Analogues  
General directions: All chemicals were purchased from Aldrich Chimica 
(Milan, Italy) and were of the highest purity. All solvents were reagent grade 
and were purified and dried by standard methods when necessary. All reactions 
requiring anhydrous conditions were conducted under a positive atmosphere of 
nitrogen in oven-dried glassware. Standard syringe techniques were used for the 
anhydrous addition of liquids. Reactions were routinely monitored by TLC 
performed on aluminum-backed silica gel plates (Merck DC, Alufolien 
Kieselgel 60 F254) with spots visualized by UV light (ƛ= 254, 365 nm) or using 
a KMnO4 alkaline solution. Solvents were removed using a rotary evaporator 
operating at a reduced pressure of ≈ 10 Torr. Organic solutions were dried over 
anhydrous Na2SO4. Chromatographic separations were performed on silica gel 
(silica gel 60, 0.015–0.040 mm; Merck DC) columns. Melting points were 
determined on a Stuart SMP30 melting point apparatus in open capillary tubes 
and were uncorrected. Infrared (IR) spectra were recorded neat with a Shimadzu 
IR Affinity-1 FTIR fitted with a MIRacle 10 single reflection ATR accessory at 
room temperature. 1H and 13C NMR spectra were recorded at 300 MHz and 75 
MHz, respectively, with a Bruker Avance 300 spectrometer. Chemical shifts are 
reported in d (ppm) relative to the internal reference tetramethylsilane (TMS). 
Mass spectra were recorded with a Finnigan LCQ DECA TermoQuest (San 
Jose, USA) mass spectrometer in electrospray-positive and -negative ionization 
modes (ESI-MS). The purity of the test compounds was established by 
combustion analysis, confirming purity ≥95%.  
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5.1.1 General procedure for the synthesis of derivatives 2a–d:  
A stirred solution of the appropriate alkyl aldehyde (4.00 mmol) and 2,4-
pentanedione (acetylacetone) (4.40 mmol) in anhydrous methylene chloride (3 
mL) was treated with piperidine (0.08 mmol) and acetic acid (0.08 mmol) at 0 
°C. The reaction mixture was stirred at room temperature for 1 h (TLC 
monitoring), diluted with methylene chloride (50 mL), washed with brine (3_10 
mL), and dried (Na2SO4). After removing the solvent, the crude residue was 
purified by column chromatography on silica gel (n-hexane/EtOAc) to afford 
the title compounds. 
 
3-Pentylidenepentane-2,4-dione (2a, EML319): Colorless oil (619 mg, 92%): 
1H NMR (300 MHz, CDCl3): δ = 6.67 (t, J=7.7 Hz, 1 H), 2.30 (s, 6H), 2.28–
2.15 (m, 2 H), 1.52–1.42 (m, 2 H), 1.41–1.31 (m, 2 H), 0.92 ppm (t, J=7.1 Hz, 
3H); 13C NMR (75 MHz, CDCl3): δ = 203.5, 197.2, 146.9, 145.4, 30.9, 29.5, 
26.1, 22.5, 13.9 ppm  IR (neat):  ̅ =2959, 2932, 2862, 1705, 1667, 1628 cm-1; 
ESI-MS m/z: 169 [M+H]+; Anal. calcd for C10H16O2 : C 71.39, H 9.59, found: 
C 71.54, H 9.61. 
 
3-Dodecylidenepentane-2,4-dione (2b, EML318): Colorless oil (991 mg, 93%): 
1H NMR (300 MHz, CDCl3): δ = 6.71 (t, J=7.7 Hz, 1 H), 2.35 (s, 6H), 2.28–
2.18 (m, 2 H), 1.53–1.42 (m, 2 H), 1.34–1.22 (m, 16H), 0.89 ppm (t, J=6.5 Hz, 
3H); IR (neat):  ̅ =2955, 2924, 2855, 1705, 1667, 1628 cm-1; ESI-MS m/z: 267 
[M+H]+; Anal. Calcd for C17H30O2 : C 76.64, H 11.35, found: C 76.83, H 11.38. 
 
3-Tetradecylidenepentane-2,4-dione (2c, EML317): Colorless oil (1095 mg, 
93%): 1H NMR (300 MHz, CDCl3): δ = 6.66 (t, J=7.7 Hz, 1 H), 2.27 (s, 6H), 
2.25–2.13 (m, 2 H), 1.51–1.40 (m, 2 H), 1.28–1.16 (m, 20H), 0.86 ppm (t, J=6.5 
Hz, 3H); IR (neat):  ̅ =2924, 2855, 1713, 1670, 1624 cm-1; ESI-MS m/z: 295 
[M+H]+; Anal. calcd for C19H34O2 : C 77.50, H 11.64, found: C 77.69, H 11.67. 
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3-Pentadecylidenepentane-2,4-dione (2d, EML76): Colorless oil (1098 mg, 
89%): 1H NMR (300 MHz, CDCl3): δ = 6.70 (t, J=7.7 Hz, 1 H), 2.34 (s, 6H), 
2.28–2.19 (m, 2 H), 1.54–1.48 (m, 2 H), 1.38–1.26 (m, 22H), 0.99 ppm (t, J=6.3 
Hz, 3H); 13C NMR (75 MHz, CDCl3): δ = 203.7, 197.2, 147.1, 145.3, 32.1, 31.8, 
29.8, 29.6, 29.5, 28.8, 26.2, 26.2, 22.8, 14.3 ppm; IR (neat):  ̅ =2916, 2851, 
1701, 1664, 1636 cm-1; ESI-MS m/z: 309 [M+H]+; Anal. calcd for C20H36O2: C 
77.87, H 11.76, found: C 78.05, H 11.79. 
 
3-Hexadecylidenepentane-2,4-dione (2e, EML320): Colorless oil (1238 mg, 
96%): 1H NMR (300 MHz, CDCl3): δ = 6.66 (t, J=7.7 Hz, 1 H), 2.28 (s, 6H), 
2.26–2.16 (m, 2 H), 1.53–1.43 (m, 2 H), 1.30–1.23 (m, 24H), 0.86 ppm (t, J=6.3 
Hz, 3H); IR (neat):  ̅ =2916, 2851, 1701, 1663, 1636 cm-1; ESI-MS m/z: 323 
[M+H]+; Anal. calcd for C21H38O2 : C 78.20, H 11.88, found: C 78.41, H 11.91. 
5.1.2 General procedure for the synthesis of derivatives 3a–d: 
Derivatives 3a–d were prepared by reacting the appropriate alkyl aldehyde and 
ethyl 3-oxobutanoate (for compounds 3a,b) or tert-butyl 3-oxobutanoate (for 
compounds 3c,d), according to the procedure used for derivatives 2a–e. The 
crude residue was purified by column chromatography on silica gel (n-
hexane/EtOAc) to afford the title compounds as a mixture of E and Z isomers. 
 
Ethyl 2-acetylhexadec-2-enoate (3a, EML329): Low-melting-point white solid 
(934 mg, 72%): 1:1 mixture of geometric isomersa and b; 1H NMR (300 MHz, 
CDCl3): δ = 6.92 (t, J=7.7 Hz, 1H, isomer a), 6.85 (t, J=7.7 Hz, 1H, isomer b), 
4.31 (q, J=7.1 Hz, 2H, isomer b), 4.25 (q, J=7.1 Hz, 2H, isomer a), 2.36–2.27 
(m, 5H, isomer b and 3H, isomer a), 2.25–2.21 (m, 2H, isomer a), 1.55–1.40 
(m, 2H, isomer a and 2H isomer b), 1.30–1.21 (m, 23 H, isomer a and 23H 
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isomer b), 0.88 ppm (br t, J=6.3 Hz, 3H, isomer a and 3H, isomer b); IR (neat): 
 ̅ =2922, 2853, 1728, 1701, 1638, 1622 cm-1; ESI-MS m/z: 325 [M+H]+; Anal. 
calcd for C20H36O3: C 74.03, H 11.18, found: C 73.92, H 11.20. 
 
Ethyl 2-acetylheptadec-2-enoate (3b, EML330): Low-melting-point white solid 
(1056 mg, 78%): 1:1 mixture of geometric isomers a and b; 1H NMR (300 MHz, 
CDCl3): δ = 6.91 (t, J=7.7 Hz, 1H, isomer a), 6.83 (t, J=7.7 Hz, 1H, isomer b), 
4.29 (q, J=7.1 Hz, 2H, isomer b), 4.23 (q, J=7.1 Hz, 2H, isomer a), 2.36–2.27 
(m, 5H, isomer b and 3H, isomer a), 2.27–2.18 (m, 2H, isomer a), 1.54–1.40 
(m, 2H, isomer a and 2H isomer b), 1.34–1.16 (m, 25 H, isomer a and 25H 
isomer b), 0.86 ppm (br t, J=6.3 Hz, 3H, isomer a and 3H, isomer b); 13C NMR 
(75 MHz, CDCl3): δ = 201.2, 195.2, 166.7, 164.8, 149.2, 148.8, 137.7, 137.2, 
61.3, 32.0, 30.1, 29.8, 29.6, 29.5, 28.7, 28.5, 27.0, 22.8, 14.3, 14.2 ppm; IR 
(neat):  ̅ =2913, 2851, 1717, 1670, 1643 cm-1; ESI-MS m/z: 339 [M+H]+; Anal. 
calcd for C21H38O3: C 74.51, H 11.31, found: C 74.37, H 11.33. 
 
tert-Butyl 2-acetylhexadec-2-enoate (3c, EML331): Low-melting-point white 
solid (1072 mg, 76%): 1:1 mixture of geometric isomers a and b; 1H NMR (300 
MHz, CDCl3): δ = 6.80 (t, J=7.9 Hz, 1H, isomer a), 6.75 (t, J=7.8 Hz, 1H, isomer 
b), 2.33–2.27 (m, 5H, isomer b and 3H, isomer a), 2.25–2.14 (m, 2H, isomer a), 
1.55–1.40 (m, 11H, isomer a and 11H isomer b), 1.30–1.21 (m, 20 H, isomer a 
and 20H isomer b), 0.88 ppm (br t, J=6.5 Hz, 3H, isomer a and 3H, isomer b); 
IR (neat):  ̅ =2924, 2855, 1724, 1701, 1636, 1620 cm-1; ESI-MS m/z: 375 
[M+Na]+; Anal. calcd for C22H40O3 : C 74.95, H 11.44, found: C 74.79, H 11.43. 
 
tert-Butyl 2-acetylheptadec-2-enoate (3d, EML332): Low-melting-point white 
solid (1056 mg, 72%): 1:1 mixture of geometric isomers a and b; 1H NMR (300 
MHz, CDCl3): δ = 6.80 (t, J=7.9 Hz, 1H, isomer a), 6.75 (t, J=7.8 Hz, 1H, isomer 
b), 2.33–2.27 (m, 5H, isomer b and 3H, isomer a), 2.25–2.14 (m, 2H, isomer a), 
- 85 - 
1.55–1.40 (m, 11H, isomer a and 11H isomer b), 1.30–1.21 (m, 22 H, isomer a 
and 22H isomer b), 0.88 ppm (br t, J=6.5 Hz, 3H, isomer a and 3H, isomer b); 
IR (neat):  ̅ =2913, 2851, 1717, 1686, 1620 cm-1; ESI-MS m/z: 389 [M+Na]+; 
Anal. calcd for C23H42O3 : C 75.36, H 11.55, found: C 75.21, H 11.54. 
5.1.3 General procedure for the synthesis of derivatives 4a–b: 
Derivatives 4a–b were prepared by reacting the appropriate alkyl aldehyde and 
malonic acid according to the procedure used for derivatives 2a–e. The crude 
residue was purified by column chromatography on silica gel (CH2Cl2/MeOH) 
to afford the title compounds. 
 
2-Tetradecylidenemalonic acid (4a, EML341): White solid (991 mg, 83%): mp: 
69–708C; 1H NMR (300 MHz, [D6]DMSO): δ = 6.99 (t, J=7.5 Hz, 1H), 2.42–
2.29 (m, 2 H), 1.44–1.33 (m, 2H), 1.32–1.15 (m, 20H), 0.85 ppm (t, J=6.2 Hz, 
3H); IR (neat):  ̅ =2953, 2918, 2851, 1735, 1720, 1697, 1568 cm-1; ESI-MS m/z: 
297 [M-H]-; Anal. calcd for C17H30O4 : C 68.42, H 10.13, found: C 68.27, H 
10.15. 
 
2-Pentadecylidenemalonic acid (4b, EML264): White solid (975 mg, 78%): 
mp: 73–758C; 1H NMR (300 MHz, [D6]DMSO): δ = 6.88 (t, J=7.6 Hz, 1H), 
2.41–2.27 (m, 2 H), 1.49–1.38 (m, 2H), 1.34– 1.14 (m, 22 H), 0.85 ppm (t, J=6.3 
Hz, 3H); 13C NMR (75 MHz, DMSO): δ = 169.8, 167.1, 147.3, 129.8, 31.3, 
29.1, 28.8, 22.1, 
13.8 ppm; IR (neat):  ̅ =2954, 2916, 2848, 1735, 1710, 1697, 1568 cm-1; ESI-
MS m/z: 311 [M-H]-; Anal. calcd for C18H32O4: C 69.19, H 10.32, found: C 
69.05, H 10.34. 
5.1.4 General procedure for the synthesis of derivatives 5a–b: 
A mixture of TFA and CH2Cl2 (1:3, 12 mL) was added to ester derivatives 3c 
or 3d (1.00 mmol). The reaction was stirred at room temperature for 30 min and 
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then concentrated in vacuo to give the title compounds as a mixture of E and Z 
isomers. 
 
2-Acetylhexadec-2-enoic acid (5a, EML333): Low-melting-point white solid 
(284 mg, 96%): 2:1 mixture of geometric isomers a and b; 1H NMR (300 MHz, 
CDCl3): δ = 10.90 (br s, 1H, isomer a and 1H isomer b), 7.41 (t, J=7.2 Hz, 1H, 
isomer a), 7.16 (t, J=7.8 Hz, 1H, isomer b), 2.88–2.78 (m, 2H, isomer a), 2.46 
(s, 3H, isomer a), 2.40 (s, 3H, isomer b), 2.35–2.25 (m, 2H, isomer b), 1.62–
1.40 (m, 2H, isomer a and 2H isomer b), 1.30–1.21 (m, 20 H, isomer a and 20H 
isomer b), 0.88 ppm (br t, J=6.3 Hz, 3H, isomer a and 3H, isomer b); IR (neat): 
 ̅ =2916, 2851, 1713, 1682, 1624 cm-1; ESI-MS m/z: 297 [M+H]+; Anal. calcd 
for C18H32O3: C 72.93, H 10.88, found: C 72.80, H 10.90. 
 
2-Acetylheptadec-2-enoic acid (5b, EML334): Low-melting-point white solid 
(292 mg, 94%): 2:1 mixture of geometric isomers a and b; 1H NMR (300 MHz, 
CDCl3): δ = 10.90 (br s, 1H, isomer a and 1H isomer b), 7.53 (t, J=7.1 Hz, 1H, 
isomer a), 7.38 (t, J=7.7 Hz, 1H, isomer b), 3.00–2.91 (m, 2H, isomer a), 2.50 
(s, 3H, isomer a), 2.46 (s, 3H, isomer b), 2.45–2.35 (m, 2H, isomer b), 1.65–
1.47 (m, 2H, isomer a and 2H isomer b), 1.40–1.15 (m, 22 H, isomer a and 22H 
isomer b), 0.88 ppm (br t, J=6.4 Hz, 3H, isomer a and 3H, isomer b); 13C NMR 
(75 MHz, CDCl3): δ = 201.9, 201.1, 169.0, 165.5, 164.0, 153.7, 134.4, 131.0, 
32.0, 31.4, 31.3, 30.0, 29.8, 29.6, 29.5, 28.7, 26.7, 22.8, 14.2 ppm; IR (neat): ̅ 
=2922, 2853, 1717, 1684, 1636 cm-1; ESI-MS m/z: 311 [M+H]+; Anal. calcd for 
C19H34O3: C 73.50, H 11.04, found: C 73.35, H 11.06. 
5.1.5 General procedure for the synthesis of derivatives 6a,b-8a–f:  
To a solution of 3-(ethoxymethylene)-2,4-pentanedione 9 (1.00 mmol) in 
anhydrous THF (3 mL), the appropriate alkylamine (1.00 mmol) or alkylthiol 
(2.00 mmol) was added, and the reaction mixture was stirred at reflux for 2 h 
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(monitored by TLC). After cooling at room temperature, the solvent was 
removed, and the crude residue was purified by column chromatography on 
silica gel (CH2Cl2/EtOAc) to afford the title compounds. 
Dodecanethiol, dodecanamine, and tridecanamine used for the preparation of 
derivatives 6a, 8a, and 8b, respectively, were commercially available. 
Tridecanethiol used for the synthesis of 6b and N-ethyldodecan-1-amine, N-
ethyltridecan-1-amine, N-benzyldodecan-1-amine, and N-benzyltridecan-1-
amine used for the synthesis of derivatives 8c, 8d, 8e, 8f, respectively, were 
prepared by standard synthetic procedures. 
 
3-(Dodecylthiomethylene)pentane-2,4-dione (6a, EML327): Low-melting- 
point white solid (288 mg, 92%): 1H NMR (300 MHz, CDCl3): δ = 8.17 (s, 1 
H), 2.83 (t, J=7.4 Hz, 2 H), 2.47 (s, 3 H), 2.38 (s, 3H), 1.79–1.63 (m, 2 H), 1.48–
1.37 (m, 2H), 1.34–1.16 (m, 16 H), 0.88 ppm (t, J=6.5 Hz, 3H); IR (neat): ̅ 
=2951, 2920, 2847, 1659, 1643 cm-1; ESI-MS m/z: 313 [M+H]+; Anal. calcd for 
C18H32O2S: C 69.18, H 10.32, S 10.26, found: C 69.32, H 10.34, S 10.27. 
 
3-(Tridecylthiomethylene)pentane-2,4-dione (6b, EML328): Low-melting- 
point white solid (307 mg, 94%): 1H NMR (300 MHz, CDCl3): δ = 8.16 (s, 1 
H), 2.83 (t, J=7.4 Hz, 2 H), 2.47 (s, 3 H), 2.38 (s, 3H), 1.78–1.65 (m, 2 H), 1.48–
1.37 (m, 2H), 1.33–1.19 (m, 18 H), 0.88 ppm (t, J=6.5 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ = 197.7, 194.7, 162.6, 134.2, 38.3, 32.1, 31.1, 30.2, 29.8, 29.6, 
29.3, 28.6, 27.8, 22.8, 14.2 ppm; IR (neat):  ̅ =2951, 2917, 2847, 1659, 1643 
cm-1; ESI-MS m/z: 327 [M+H]+; Anal. calcd for C19H34O2S: C 69.89, H 10.50, 
S 9.82, found: C 70.05, H 10.52, S 9.84. 
 
3-((Dodecylamino)methylene)pentane-2,4-dione (8a, EML321): Low-melting-
point pale-yellow solid (287 mg, 97%): 1H NMR (300 MHz, CDCl3): δ = 11.07 
(br s, 1H), 7.71 (d, J=12.3 Hz, 1H), 3.38–3.31 (m, 2H), 2.48 (s, 3H), 2.26 (s, 
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3H), 1.67–1.56 (m, 2 H), 1.41–1.19 (m, 18H), 0.88 ppm (t, J=6.4 Hz, 3H); IR 
(neat):  ̅ =3202, 2916, 2847, 1651, 1605, 1582 cm-1; ESI-MS m/z: 296 [M+H]+; 
Anal. calcd for C18H33NO2 : C 73.17, H 11.26, N 4.74, found: C 73.33, H 11.28, 
N 4.75. 
 
3-((Tridecylamino)methylene)pentane-2,4-dione (8b, EML322): Low-melting-
point pale-yellow solid (303 mg, 98%): 1H NMR (300 MHz, CDCl3): δ = 11.07 
(br s, 1H), 7.72 (d, J=13.7 Hz, 1H), 3.41–3.29 (m, 2H), 2.48 (s, 3H), 2.24 (s, 
3H), 1.68–1.58 (m, 2 H), 1.34–1.19 (m, 20H), 0.88 ppm (t, J=6.5 Hz, 3H); 13C 
NMR (75 MHz, CDCl3): δ = 200.4, 194.4, 160.0, 111.5, 50.6, 32.0, 30.7, 29.8, 
29.6, 29.5, 29.3, 27.5, 26.6, 22.8, 14.2 ppm; IR (neat):  ̅ =3202, 2916, 2851, 
1651, 1605, 1585 cm-1; ESI-MS m/z: 310 [M+H]+; Anal. Calcd for C19H35NO2 
: C 73.74, H 11.40, N 4.53, found: C 73.94, H 11.42, N 4.54. 
 
3-((Dodecyl(ethyl)amino)methylene)pentane-2,4-dione (8c, EML323): Low-
melting-point pale-yellow solid (301 mg, 93%): 1H NMR (300 MHz, CDCl3): δ 
= 7.36 (s, 1 H), 3.32–3.20 (m, 4 H), 2.32 (s, 6H), 1.58–1.42 (m, 2 H), 1.33–1.20 
(m, 18H), 1.19–1.03 (m, 3 H), 0.87 ppm (t, J=6.3 Hz, 3H); IR (neat):  ̅ =2924, 
2855, 1655, 1620, 1578 cm-1; ESI-MS m/z: 324 [M+H]+; Anal. calcd for 
C20H37NO2: C 74.25, H 11.53, N 4.33, found: C 74.47, H 11.55, N 4.34. 
 
3-((Ethyl(tridecyl)amino)methylene)pentane-2,4-dione (8d, EML324): Low-
melting-point pale-yellow solid (317 mg, 94%): 1H NMR (300 MHz, CDCl3): δ 
= 7.36 (s, 1 H), 3.39–3.18 (m, 4 H), 2.32 (s, 6H), 1.62–1.37 (m, 2 H), 1.35–1.19 
(m, 20H), 1.18–1.05 (m, 3 H), 0.87 ppm (t, J=6.4 Hz, 3H); IR (neat):  ̅ =2920, 
2851, 1659, 1612, 1578 cm-1; ESI-MS m/z: 338 [M+H]+; Anal. calcd for 
C21H39NO2: C 74.72, H 11.65, N 4.15, found: C 74.94, H 11.68, N 4.16. 
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3-((Benzyl(dodecyl)amino)methylene)pentane-2,4-dione (8e, EML325): Pale-
yellow solid (370 mg, 96%): mp: 53–568C; 1H NMR (300 MHz, CDCl3): δ = 
7.49 (s, 1H), 7.38–7.27 (m, 3H), 7.18–7.10 (m, 2 H), 4.44 (s, 2H), 3.37–3.20 
(m, 2 H), 2.15 (s, 6H), 1.62–1.46 (m, 2 H), 1.32–1.19 (m, 18H), 0.88 ppm (t, 
J=6.5 Hz, 3H); IR (neat):  ̅ =2916, 2851, 1670, 1574 cm-1; ESI-MS m/z: 386 
[M+H]+; Anal. calcd for C25H39NO2: C 77.87, H 10.20, N 3.63, found: C 78.10, 
H 10.22, N 3.64. 
 
3-((Benzyl(tridecyl)amino)methylene)pentane-2,4-dione (8f, EML326): Pale-
yellow solid (388 mg, 97%): mp: 61–648C; 1H NMR (300 MHz, CDCl3): δ = 
7.49 (s, 1 H), 7.39–7.28 (m, 3 H), 7.20–7.11 (m, 2 H), 4.43 (s, 2H), 3.34–3.17 
(m, 2 H), 2.15 (s, 6H), 1.66–1.48 (m, 2 H), 1.31–1.20 (m, 20H), 0.88 ppm (t, 
J=6.4 Hz, 3H); IR (neat):  ̅ =2916, 2851, 1674, 1574 cm-1; ESI-MS m/z: 400 
[M+H]+; Anal. calcd for C26H41NO2: C 78.15, H 10.34, N 3.51, found: C 78.38, 
H 10.36, N 3.52. 
 
5.2 Surface Plasmon Resonance 
SPR analyses were performed on a Biacore 3000 optical biosensor equipped 
with research-grade CM5 sensor chips (Biacore AB). Recombinant 
p300/KAT3B (Enzo Life Sciences, # BML-SE451; Gen-Bank accession no. 
NM_001429) and PCAF/KAT2B (Biovision, # 1137–100; GenBank accession 
n. NM003884) HAT domains were used in this analysis. Proteins (10 μg/mL in 
100 mM sodium acetate, pH 4.5) were immobilized on individual flow cells of 
the sensor chip at a flow rate of 10 μL/min using standard amine coupling 
protocols to obtain densities of 8–9 kRU. Myoglobin was used as a negative 
control, and one flow cell was left empty for background subtraction. All 
compounds were dissolved in DMSO (100%) to obtain 50 mM solutions, and 
they were diluted in HBS-P (10 mM HEPES pH 7.4, 0.15 M NaCl, 0.005% 
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surfactant P20) while maintaining a final 0.2% DMSO concentration. Binding 
experiments were performed at 25 °C using a flow rate of 30 μL/min with 120 
s association monitoring and 200 s dissociation monitoring. 
Surface regeneration was performed when necessary by a 10 s injection of 5 
mM NaOH. The simple 1:1 Langmuir binding fit model of BIAevaluation 
software (version 4.1) was used for determining equilibrium dissociation 
constants (KD) and kinetic dissociation (kd) and association (ka) constants 
using Equations (1) and (2), where R represents the response unit, and C is the 
concentration of the analyte. 
 
𝑑𝑅/𝑑𝑡 = 𝐾𝑎 𝐶(𝑅𝑚𝑎𝑥 − 𝑅) − 𝑘𝑑 𝑅       (1) 
𝐾𝐷 = 𝐾𝑑/𝐾𝑎                                           (2) 
 
5.3 Histone acetyl transferase IC50 profiling 
The effect of the derivatives on the catalytic activity of PCAF and p300 was 
determined with a HotSpot HAT activity assay by Reaction Biology 
Corporation (Malvern, PA, USA) according to the company’s standard 
operating procedure. Briefly, the recombinant catalytic domains of PCAF (aa 
492–658) or p300 (aa 1284–1673) were incubated with histone H3 as a substrate 
(5 μM) and [acetyl-3H]-acetyl coenzyme A (3.08 μM) as an acetyl donor in 
reaction buffer (50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 0.1 mM EDTA, 1 mM 
DTT, 1 mM PMSF, 1% DMSO) for 1 h at 30 °C in the presence or absence of 
a dose titration of the compounds. Histone H3 acetylation was assessed by liquid 
scintillation. Anacardic acid or curcumin served as controls that inhibit PCAF 
or p300 activity, respectively. Data were analysed using Excel and GraphPad 
Prism software (version 6.0, GraphPad Software) for IC50 curve fits using 
sigmoidal dose-response (variable slope) equations. 
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5.4 Cell viability assay 
The U937 cell line (derived from a human histocytic lymphoma) was cultured 
in RPMI-1640 medium (Sigma) supplemented with 10% (v/v) fetal bovine 
serum (Sigma), 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma) at 
37 °C in a 5% CO2 atmosphere. U937 cell viability was measured using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A 
total of 200 μL of cells seeded in 96-well microtiter plates (2.5x 105 cells/mL) 
were exposed for 24 h to different concentrations of selected compounds in 
media containing 0.2% DMSO. The mitochondrial-dependent reduction of 
MTT to formazan was used to assess cell viability. Experiments were performed 
in quadruplicate, and all values are expressed as the percentage of the control 
containing 0.2% DMSO. 
5.5 Cell-cycle analysis 
For cell-cycle analysis, 500 μL of U937 cells (2.5x 105 cells/mL) were seeded 
in 24-well plates and incubated with selected compounds at different 
concentrations. After 24 or/and 72 h of treatment, 500 μL of hypotonic buffer 
(33 mM sodium citrate, 0.1% Triton X-100, 50 μg/mL propidium iodide) was 
added to cell suspensions. Cells were analyzed with a FACScan flow cytometer 
(Becton Dickinson, CA), using Mod FitLT (version 3.2, Verity Software House, 
Inc., ME, USA) for quantitative analysis of cell-cycle distribution. All 
experiments were performed at least in triplicate. 
5.6 Western blot analysis of acetyl-lysines 
U937 (10 mL, 2.5x 105 cells/mL), HeLa and C33A (sub-confluent) cells were 
seeded and incubated with compounds at different concentrations, and after 24, 
48 and 72h, the cells were harvested and washed three times with 1X PBS 
(Sigma) and then resuspended in lysis buffer (10 mM Tris pH 8, 1 mM KCl, 1.5 
mM MgCl2, and 1 mM DTT) supplemented with a protease inhibitor cocktail 
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(Sigma). All subsequent manipulations were performed at 4 °C. After 
incubation for 1 h on a rotator, nuclei were collected by centrifugation for 10 
min at 10000g. The nuclear pellets were suspended in 0.4 N H2SO4, and after 
incubation for 2 h, were centrifuged for 15 min at 12000g. Histones contained 
in the supernatant were precipitated by adding TCA to a final concentration of 
33% and incubating overnight at 4 °C. After centrifugation at 10000g for 30 
min, the histone pellets were washed twice with acetone, air-dried, and finally 
redissolved in 50 μL of water. Protein concentrations were determined using the 
Bradford assay, and 1 μg of histones from each sample was loaded onto a 15% 
SDS-PAGE gel and transferred to a nitrocellulose membrane. The following 
primary antibodies were used: anti-histone H4 (acetyl K5) (Abcam, # ab61236); 
anti-histone H3 (acetyl K9) (Abcam, # ab10812); anti-histone H3 (Abcam, # 
ab1791). 
5.7 Garcinol Derivatives Stability Assays 
Compounds 15b–h, 9a and 12a were dissolved in PBS to reach a final 
concentration of 100 μM (5% DMSO). 5 μL of the prepared solutions were 
analysed by HPLC after 2, 10, 30, 60 min and 24 h. Spectra were recorded on a 
Shimadzu SPD 20A UV/vis detector (λ = 220 nm) using C-18 column 
Phenomenex Synergi Fusion RP 80A (75mm × 4.60 mm; 4 μm) at 25 °C using 
a mobile phase A (water + 0.1% TFA) and B (MeCN + 0.1% TFA) at a flow 
rate of 1 mL/min. 
5.8 Parallel Artificial Membrane Permeability Assay (PAMPA) 
Donor solution (0.5 mM) was prepared by diluting 1 mM dimethyl sulfoxide 
(DMSO) compound stock solution using phosphate buffer (pH 7.4, 0.01 M). 
Filters were coated with 5 μL of a 1% (w/v) dodecane solution of 
phosphatidylcholine. Donor solution (150 μL) was added to each well of the 
filter plate. To each well of the acceptor plate were added 300 μL of solution 
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(50% DMSO in phosphate buffer). Compounds were tested in triplicate. The 
sandwich was incubated for 24 h at room temperature under gentle shaking. 
After the incubation time, the sandwich plates were separated and 250 μL of the 
acceptor plate were transferred to a UV quartz microtiter plate and measured by 
UV spectroscopy, using a Multiskan GO microplate spectrophotometer 
(Thermo Scientific) at 250-500 nm at step of 5 nm. Reference solutions (250 
μL) were prepared diluting the sample stock solutions to the same concentration 
as that with no membrane barrier. The apparent permeability value Papp is 
determined from the ratio r of the absorbance of compound found in the acceptor 
chamber divided by the theoretical equilibrium absorbance (determined 
independently) applying the Faller modification of Sugano equation: 
𝑃𝑎𝑝𝑝 = − (
𝑉𝐷 ∗ 𝑉𝑅
(𝑉𝐷 + 𝑉𝑅)𝐴𝑡
) ∗ ln(1 − 𝑟) 
 
In this equation, VR is the volume of the acceptor compartment (0.3 cm3), VD 
is the donor volume (0.15 cm3), A is the accessible filter area (0.24 cm2), and t 
is the incubation time in seconds. 
5.9 Kinetic Characterization of 15h Inhibitor  
To explore the mechanisms of p300 inhibition by 15h, we took advantage of an 
AlphaLisa homogeneous proximity immunoassay. Reactions were performed as 
suggested by manufacturer, briefly each assay containing 5 nM p300 (Enzo 
LifeScience, # BML-SE451), 3 μM Acetyl CoA, and 50 nM biotinylated H3 
(1−21) peptide (Anaspec, # 61702) in 10 μL of assay buffer (50 mM Tris-HCl, 
pH 8.0, 0.1 mM EDTA, 1 mM DTT, 0.01% Tween-20, 0.01% BSA, 330 nM 
TSA) was incubated at room temperature for 15 min in a White opaque 
OptiPlate-384 (PerkinElmer, # 6007299). Reactions were stopped by adding 
garcinol (final concentration 50 μM) and anti-acetyl histone H3 lysine 9 
(H3K9Ac) acceptor beads (PerkinElmer, # AL114, final concentration 20 
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μg/mL). After 60 min of incubation at room temperature, 20 μg/mL final 
concentration of Alpha Streptavidin Donor beads (PerkinElmer, # 6760002) 
were added in subdued light and incubated in the dark for 30 min at room 
temperature. Signals were read in Alpha mode with a PerkinElmer EnSpire 
Multilabel plate reader. To determine the pattern of inhibition of 15h, different 
set of assays were performed maintaining one substrate constant and varying 
the other in the presence of three different concentrations of inhibitor (0, 5, and 
10 μM). In the first set of experiments, H3 peptide was varied from 1.5 to 50 
nM while holding AcCoA constant at 3 μM, and in the second set AcCoA was 
varied from 15.6 nM to 1 μM while holding H3 peptide constant at 50 nM. 
Reactions were performed in duplicate and data were fitted to determine the 
kind of inhibition. 
5.10 His-FLAG-SETD8 expression and purification  
The DNA sequence encoding human SETD8 (residues 51-383) was cloned as 
His-FLAG fusion protein into the pET-28 b (+) vector. The vector, generously 
provided by D. Reinberg, was transformed into BLR(DE3)pLysS competent 
cells and the protein was overexpressed in 1 L of LB at 37 °C by the addition of 
0.1 mM IPTG when the OD600= 0.6. After 6 h at 25 °C, the cells harbouring the 
expressed protein were pelleted at 5000g for 15 min at 4 °C and resuspended in 
40 mL of Lysis Buffer (Tris HCl 50 mM pH 8, NaCl 100 mM, DTT 0.1 mM), 
adding protease inhibitors cocktail (Sigma). Cells were lysed using a sonicator 
(Vibra-Cells, Sonics) and cell debris were pelleted at 10000g for 30 min at 4 °C. 
The clarified lysate was filtered using a 0,45 µm syringe filter and loaded onto 
a 1-mL HisTrap HP column (GE Healthcare, # 17-5247-01) using an AKTA 
FPLC (GE Healthcare) at the flow rate of 1 mL/min. The protein was eluted 
using the elution buffer (Phosphate Buffer 20 mM pH 7.4, NaCl 0.5 M, 
Imidazole 0.5 M) over 10 column volumes. Fractions containing the protein 
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were confirmed by sodium dodecyl sulfate-polyacrilamide gel electrophoresis 
(SDS-PAGE) and then pooled. 
5.11 SETD8 Labelling and Microscale Thermophoresis 
experiments 
Fluorescence labelling of SETD8 was performed following the protocol for N-
hydroxysuccinimide (NHS) coupling of the dye NT647 (NanoTemper 
Technologies) to lysine residues. Briefly, 100 µL of a 10 µM solution of SETD8 
protein in labelling buffer was mixed with 100 µL of 30 µM NT647-NHS 
fluorophore (NanoTemper Technologies) in labelling buffer and incubated for 
30 min at room temperature (RT). Unbound fluorophores were removed by size-
exclusion chromatography with MST buffer (50 mM Tris, pH 7.8, 150 mM 
NaCl, 10 mM MgCl2) as running buffer. The degree of labelling was determined 
using extinction coefficients ε280 = 20800 M
–1 cm–1 for SETD8 and ε653 = 
250000 M–1 cm–1 for the NT647 fluorophore.  
Prior to MST experiment, aliquots of NT647-SETD8 were thawed on ice and 
centrifuged for 15 min at 4 °C and 12000g to remove protein aggregates. 
A Monolith NT.115 (NanoTemper Technologies) was used to measure 
equilibrium binding between SETD8 and EPI-009. Standard treated capillaries 
were obtained from NanoTemper Technologies. The sample tray format 
allowed to process automatically up to 16 capillaries for Kd determination in 
one experiment. Measurements were performed at 80% LED and 80% MST 
power. 
For Kd determination, the non-fluorescent binding EPI-009 was titrated (highest 
concentration 500 μM) against a fixed concentration of 100 nM of the 
fluorescent partner SETD8. After preparing the serial dilution, samples were 
loaded into MST capillaries. Capillary scan control led to constant initial 
fluorescence intensity in the 16 capillaries throughout the titration series. After 
the measurement, the MO analysis software calculates the extent of binding by 
plotting the ratio between the fluorescence when the laser is on and the 
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fluorescence before the laser is turned on. The software automatically calculated 
the Kd by using the mass action equation via the NanoTemper tool. 
5.12 SETD8 cloning in pGEX-4T-1  
SETD8 nucleotide sequence from pET-28 b (+) was amplified by PCR, using 
the designed following primers: 
  BamHI 
5’-ataggatccaagccctccgcggtg-3’ oligo FW-SETD8 
     XhoI     
5’-atactcgagctaatgcttcagccacgg-3’ oligo REV-SETD8 
The PCR reaction was carried out in a final volume of 50 μL, using 0.5 μL of 
vector, 1 μL of each primer (FW and REV) 10 μM, 1 μL of dNTPs 10 mM, 0,25 
μL of Taq Polimerase (1U/ μL), using the following amplification program: 
 2 min 95 °C 
30 sec 95 °C  
 30 sec 65 °C   X 30 cycles  
1 min 72 °C  
 15 min 72 °C  
To facilitate the cloning in the expression vector pGEX-4-T1, we used a cloning 
vector pGEM-T (Promega, # A1360): this linearized vector has a single 3´-
terminal thymidine at both ends. The T-overhangs at the insertion site greatly 
improve the efficiency of ligation of PCR products by preventing 
recircularization of the vector. The ligase reaction was performed in a final 
volume of 10 μL, incubating the DNA of SETD8 and the vector with a molar 
ratio of 1:1 for 1h at 25 °C. For the ligase reaction it was used 1 μL of T4 DNA 
ligase (3 Weiss units/ µl) (Promega, # A1360) and 5 μL of Ligation buffer mix 
2 X (Promega, # A1360). 1 μL of the ligase product was transformed into 50 μL 
JM109 high-efficiency competent cells (Promega, # L2001) with the heat-shock 
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method. Briefly, the mixture plasmidic DNA-competent cells were incubated 
for 30 minutes on ice, subsequently the cells were heat shocked for 45 sec at 
42°C and then incubated for 2 min on ice. LB medium was then added to reach 
a final volume of 1 mL and the cells were incubated at 37 °C for 1h, the 
suspension was plated out on LB/ampicillin/IPTG/X-Gal agar plates. 
Blue/white screening allowed to identify recombinant colonies, after an 
incubation of the agar plates at 37 °C overnight. 
The recombinant colonies were amplified and the plasmidic DNA was purified 
by Mini-Prep, afterwards the plasmid was digested by incubating it for 2 h at 37 
°C with the restriction enzymes BamHI and XhoI, in order to separate the 
SETD8 DNA from the vector. After the digestion, the sample was loaded on an 
agarose gel and the electrophoresis of the DNA fragments was performed in 
order to separate the band of interest (SETD8). Then, this band was excised out 
from the agarose gel and placed into a dialysis bag with some TAE buffer. The 
bag was then placed into a gel box (also containing the same buffer) and an 
electric current of 100 V was applied. After the release of Ethidium Bromide 
from the dialysis bag, the solution inside the bag was removed and the DNA 
was precipitated from the solution by the addition of 3 volumes of ethanol and 
1/10 of Sodium Acetate and storing the sample at -80 °C for 30 minutes. The 
sample was centrifuged at high speed and the pellet obtained air dried, then 
resuspended in 10 mM Tris HCl pH 8.0.  
The DNA purified by electroelution was then used for a ligase reaction with the 
expression vector pGEX-4T-1, incubating them at 16 °C overnight. The ligase 
product was then transformed with the heat-shock method (as previously 
reported) in JM109 competent cells, the colonies obtained were amplified and 
the plasmidic DNA purified to detect the recombinant ones. Finally, the DNA 
of a single recombinant colony was transformed into BLR(DE3)pLysS 
competent cells to overexpress the protein. 
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5.13 GST-SETD8 Expression and Purification 
The vector pGEX-4T-1 transformed into BLR(DE3)pLysS competent cells 
allowed the overexpression of the protein in 1 L of LB at 37 °C by the addition 
of 0.1 mM IPTG when the OD600= 0.6. After 2 h at 37 °C, the cells harbouring 
the expressed protein were pelleted at 5000g for 15 min at 4 °C and resuspended 
in 40 mL of Lysis Buffer (Tris HCl 50 mM pH 8, NaCl 100 mM, DTT 0.1 mM), 
adding protease inhibitors cocktail (Sigma). Cells were lysed using a sonicator 
(Vibra-Cells, Sonics) and cell debris were pelleted at 10000g for 30 min at 4 °C. 
The clarified lysate was filtered using a 0.45 µm syringe filter and loaded onto 
a 1-mL GSTrap HP column (GE Healthcare, # 17-5281-01) using an AKTA 
FPLC (GE Healthcare) at the flow rate of 1 mL/min. GST-SETD8 was eluted 
using the elution buffer (Tris HCl 50 mM pH 8.0, glutathione reduced 10 mM) 
over 10 column volumes. Fractions containing the protein were confirmed by 
sodium dodecyl sulfate-polyacrilamide gel electrophoresis (SDS-PAGE) and 
then pooled. 
5.14 GST-SETD8 Thrombin Cleavage 
The cleavage of GST was performed using ThrombinCleanCleavage Kit 
(Sigma, # RECOMT), following the procedure of the technical datasheet. Each 
cleavage experiment was performed using 1 mg of GST-SETD8 in a final 
volume of 1 mL. 100 μL aliquot of a 50% (v/v) suspension of thrombin agarose 
resin was centrifuged at 500g and washed three times with 500 μL of Cleavage 
Buffer 1X, afterwards the resin was resuspended in 100 μL of Cleavage Buffer 
10X, 1 mg of the protein was added and the final volume of 1 mL was reached 
with water. The cleavage reaction was incubated at two different temperatures 
(25 °C and 4 °C), with gentle agitation to keep beads in suspension, for different 
times. Analysis of cleavage reactions was performed by SDS-PAGE. 
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5.15 AlphaLISA SETD8 assay 
The assays were performed in white Optiplate-384 (PerkinElmer, # 6007299) at 
room temperature in a final volume of 25 μL, using the following Assay Buffer: 
TrisHCl 50 mM pH 8.5, NaCl 50 mM, MgCl2 5 mM, DTT 1 mM, BSA 0.01%. 
His-SETD8 (Active Motif, # 31321) (20 nM, final concentration) and GST-
SETD8 (expressed) (50 nM, final concentration) were diluted in Assay Buffer, 
then a mixture of SAM (Sigma, # A7007) (200 μM, final concentration) and 
Histone H4 (Active Motif, # 31223) (150 nM, final concentration) was added. 
The reaction was incubated for 1 h, afterwards it was stopped by adding 5 μL of 
High Salt Buffer (50 mM Tris-HCl pH 7.4, 0.1% Tween-20, 1 M NaCl, 0.3% 
poly-L-lysine). After an incubation of 15 min, a mixture of anti-Histone 
H4K20me1 Acceptor beads (PerkinElmer, # AL145) and biotinylated anti-H4 
antibody (PerkinElmer, # AL146) was prepared in Epigenetic Buffer 1X and 
added in each well, to reach a final concentration of 20 μg/mL and 1 nM 
respectively. After an incubation of 1 h, Streptavidin Donor beads 
(PerkinElmer, # 6760002) were diluted in Epigenetic Buffer 1X and added in 
each well to reach a final concentration of 20 μg/mL. After 30 minutes of 
incubation, the Alpha signal was read with the EnSpire Multilabel plate Reader 
(PerkinElmer). All incubation steps with AlphaScreen beads were performed at 
room under subdued lighting condition. 
5.16 Optimized Conditions for the Gene Reporter System 
All transient transfections were carried out using 293-T-REx cells, which were 
cultured in DMEM high glucose medium supplemented with FBS 10% + 100 
U/mL penicillin + 100 μg/mL streptomycin+ Neomicin 200 μg/mL + Blasticidin 
5 μg/mL. 200 μL of cells (1.0 x 104) were seeded in 96-well plate and after 48 
h the transfection was carried out adding in each well a transfection mix 
composed by 0.2 μL of Lipofectamine (Invitrogen, # A12621), 100 ng of vector 
pcDNA™4/TO (GAL4-SETD8) and 25 ng of β-gal for each well (the β-gal 
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reporter was used as a transfection control), diluted in Opti-MEM (Thermo 
Fisher). After 6h of incubation at 37 °C, the transfection mix was removed and 
in each well the growing medium was added, supplemented with 1 μg/mL of 
Tetracycline to induce SETD8 expression. The cells were incubated for 48 h at 
37 °C, afterwards they were harvested, lysed and the lysate was transferred in a 
white plate for the luminesce assay, using the Kit Dual-Light System (Applied 
Biosystems, # T1003) and following the procedure reported in the technical 
datasheet. The luminescent signal was read with the EnSpire Multilabel plate 
Reader (PerkinElmer) and the levels of luciferase activity were recorded. 
5.17 Tudor domains of PHF20 expression, purification and 
cleavage. 
The DNA sequence encoding the Tudor domains of human PHF20 (residues 1-
150) was cloned as GST fusion protein into the pGEX-4T-1 vector (GE 
Healthcare) using BamHI/AvaI restriction sites. The vector, generously 
provided by M. Bedford,  was transformed into BLR(DE3)pLysS competent 
cells and the protein was overexpressed in 1 L of LB at 37 °C by the addition of 
0.1 mM IPTG when the OD600= 0.6. After 4 h at 37 °C, cells harbouring the 
expressed protein were pelleted at 5000g for 15 min at 4 °C and resuspended in 
40 mL of Lysis Buffer (Tris HCl 50 mM pH 8, NaCl 100 mM, DTT 0.1 mM), 
adding protease inhibitors cocktail (Sigma). Cells were lysed using a sonicator 
(Vibra-Cells, Sonics) and cell debris were pelleted at 10000g for 30 min at 4 °C. 
The clarified lysate was filtered using a 0,45 µm syringe filter and loaded onto 
a 1-mL GSTrap HP column (GE Healthcare, # 17-5281-01) using an AKTA 
FPLC (GE Healthcare) at the flow rate of 1 mL/min. GST-protein was eluted 
using the elution buffer (Tris HCl 50 mM pH 8.0, glutathione reduced 10 mM) 
over 10 column volumes. Fractions containing the protein were confirmed by 
sodium dodecyl sulfate-polyacrilamide gel electrophoresis (SDS-PAGE) and 
then pooled. 
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The cleavage of GST was performed using ThrombinCleanCleavage Kit 
(Sigma, # RECOMT), following the procedure of the technical datasheet. 
Briefly, 100 μL aliquot of a 50% (v/v) suspension of thrombin agarose resin was 
centrifuged at 500g and washed three times with 500 μL of Cleavage Buffer 1X, 
afterwards the resin was resuspended in 100 μL of Cleavage Buffer 10X, 1 mg 
of the protein was added and the final volume of 1 mL was reached with water. 
The cleavage reaction was incubated at room temperature, with gentle agitation 
to keep beads suspended, for 6h. Analysis of cleavage reaction was performed 
by SDS-PAGE. The cleaved protein was then separated from the GST by 
anionic exchange chromatography using a Mono Q™ column (GE Healthcare, 
# 17-5166-01): a 1-mL bed volume of Mono Q™ 5/50 GL was equilibrated in 
buffer A (20 mM Tris-HCl pH 8.0); the cleaved protein was loaded onto the 
column at 1 mL/min. The column was washed with 5 column volumes of buffer 
A and eluted with buffer B (20 mM Tris-HCl pH 8.0 + 1 M NaCl), allowing the 
separation of the native protein from the cleaved GST. 
5.18 nanoDSF 
Protein thermal stability was measured in a label-free fluorimetric analysis using 
the Prometheus NT.48 (NanoTemper Technologies). Briefly, the shift of 
intrinsic tryptophan fluorescence of proteins upon temperature-induced 
unfolding was monitored by detecting the emission fluorescence at 330 and 350 
nm. Thermal unfolding was performed in nanoDSF grade standard glass 
capillaries (NanoTemper Technologies) at a heating rate of 0.5 °C per minute 
in a range from 20 °C to 95 °C, using 20 μM of protein and 100 μM of 
compounds. Protein melting points (Tm) were calculated from the first 
derivative of the ratio of tryptophan emission intensities at 330 and 350 nm.  
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5.19 Tudor Alphascreen assay optimization 
All AlphaScreen experiments described were performed at room temperature in 
white 384-well Opti-Plates (PerkinElmer, # 6007299) in a final volume of 25 
µL. For the detection of GST fusion protein, the anti-GST coated Acceptor 
beads (PerkinElmer, # AL110C) were used, while the detection of biotinylated 
peptide [Lys(Me2)20] - Histone H4 (8 - 30) (Anaspec, # AS-65419-1) was 
performed using the Streptavidin Donor Beads (PerkinElmer, # 6760002S). 
Equal concentrations of Acceptor beads and Donor beads were used in every 
experiments (5 µg/mL final concentration of each bead). All incubation steps 
with AlphaScreen beads were performed at room temperature for 1 h under 
subdued lighting conditions, and finally, the assay plates were read in an 
EnSpire Multilabel plate reader (PerkinElmer).  
The effect of UNC1215 analogues on Tudor activity was determined at a fixed 
100 μM concentration, incubating the compounds with 25 nM of the protein and 
100 nM of the substrate in reaction buffer (TrisHCl 20 mM pH 8.0, NaCl 25 
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